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SUMMARY
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently identified coronavirus that
causes the respiratory disease known as coronavirus disease 2019 (COVID-19). Despite the urgent need,
we still do not fully understand the molecular basis of SARS-CoV-2 pathogenesis. Here, we comprehensively
define the interactions between SARS-CoV-2 proteins and human RNAs. NSP16 binds to the mRNA recog-
nition domains of the U1 and U2 splicing RNAs and acts to suppress global mRNA splicing upon SARS-CoV-2
infection. NSP1 binds to 18S ribosomal RNA in the mRNA entry channel of the ribosome and leads to global
inhibition of mRNA translation upon infection. Finally, NSP8 and NSP9 bind to the 7SL RNA in the signal
recognition particle and interfere with protein trafficking to the cell membrane upon infection. Disruption of
each of these essential cellular functions acts to suppress the interferon response to viral infection. Our re-
sults uncover a multipronged strategy utilized by SARS-CoV-2 to antagonize essential cellular processes to
suppress host defenses.
INTRODUCTION
Coronaviruses are a family of viruses with notably large single-
stranded RNA genomes and broad species tropism amongmam-
mals (Graham and Baric, 2010). Recently, a coronavirus, severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was
discovered to cause the severe respiratory disease known as co-
ronavirus disease 2019 (COVID-19). It is highly transmissible in hu-
man populations, and its spreadhas resulted in a global pandemic
withmore than amillion deaths to date (Andersen et al., 2020; Zou
et al., 2020). We do not fully understand the molecular basis of
infection and pathogenesis of this virus in human cells. Accord-
ingly, there is an urgent need to understand these mechanisms
to guide the development of therapeutic agents.
SARS-CoV-2 encodes 27 proteins with diverse functional roles
in virus replication andpackaging (Bar-Onet al., 2020;Wang et al.,
2020). These include 4 structural proteins: the nucleocapsid (N;
which binds the viral RNA) and the envelope (E), membrane (M),
and spike (S) proteins, which are integral membrane proteins. In
addition, there are 16 non-structural proteins (NSP1–NSP16)
that encode the RNA-directed RNA polymerase, helicase, and
other components required for virus replication (da Silva et al.,
2020). Finally, there are 7 accessory proteins (ORF3a–ORF8)
whose function in virus replication or packaging remains largely
uncharacterized (Chen and Zhong, 2020; Finkel et al., 2020).
As obligate intracellular parasites, viruses require host cell
components to translate and transport their proteins and to
assemble and secrete viral particles (Maier et al., 2016). The
mammalian innate immune system acts to rapidly detect and
block viral infection at all stages of the virus life cycle (Chow
et al., 2018; Jensen and Thomsen, 2012; Wilkins and Gale,
2010). The primary form of intracellular virus surveillance
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engages the interferon pathway, which amplifies signals result-
ing from detection of intracellular viral components to induce a
systemic type I interferon response upon infection (Stetson
and Medzhitov, 2006). Specifically, cells contain various RNA
sensors (such as RIG-I and MDA5) that detect the presence of
viral RNAs and promote nuclear translocation of the transcription
factor IRF3, leading to transcription, translation, and secretion of
interferon (e.g., interferon [IFN]-a and IFN-b). Binding of IFN to
cognate cell-surface receptors leads to transcription and trans-
lation of hundreds of antiviral genes.
In order to successfully replicate, viruses employ a range of
strategies to counter host antiviral responses (Beachboard and
Horner, 2016). In addition to their essential roles in the viral life
cycle, many viral proteins also antagonize core cellular functions
in human cells to evade host immune responses. For example,
human cytomegalovirus (HCMV) encodes proteins that inhibit
major histocompatibility complex (MHC) class 1 display on the
cell surface by retaining MHC proteins in the endoplasmic retic-
ulum (Miller et al., 1998), polioviruses encode proteins that
degrade translation initiation factors (eIF4G) to prevent transla-
tion of 50-capped host mRNAs (Kempf and Barton, 2008; Lloyd,
2006), and influenza A encodes a protein that modulates mRNA
splicing to degrade the mRNA that encodes RIG-I (Kochs et al.,
2007; Zhang et al., 2018).
Suppression of the IFN response has recently emerged as a
major clinical determinant of COVID-19 severity (Zhang et al.,
2020), with almost complete loss of secreted IFN characterizing
the most severe cases (Hadjadj et al., 2020). The extent to which
SARS-CoV-2 suppresses the IFN response is a key character-
istic that distinguishes COVID-19 from SARS and Middle East
respiratory syndrome (MERS) (Lokugamage et al., 2020). Several
strategies have been proposed for how the related SARS- and
MERS-causing viruses may hijack host cell machinery and
evade immune detection, including repression of host mRNA
transcription in the nucleus (Canton et al., 2018), degradation
of host mRNA in the nucleus and cytoplasm (Kamitani et al.,
2009; Lokugamage et al., 2015), and inhibition of host translation
(Nakagawa et al., 2018). Nonetheless, the extent to which SARS-
CoV-2 uses these or other strategies and how they may be
executed at a molecular level remains unclear.
Understanding the interactions between viral proteins and
components of human cells is essential for elucidating their path-
ogenic mechanisms and for development of effective therapeu-
tic agents. Because SARS-CoV-2 is an RNA virus, and many of
its encoded proteins are known to bind RNA (Sola et al., 2011),
we reasoned that these viral proteins may interact with specific
human mRNAs (critical intermediates in protein production) or
non-coding RNAs (critical structural components of diverse
cellular machines) to promote virus propagation.
Here we comprehensively define the interactions between
each SARS-CoV-2 protein and human RNA. We show that 10
viral proteins form highly specific interactions with mRNAs or
noncoding RNAs (ncRNAs), including those involved in progres-
sive steps of host cell protein production. We show that NSP16
binds to the mRNA recognition domains of the U1 and U2 RNA
components of the spliceosome and acts to suppress global
mRNA splicing in SARS-CoV-2-infected human cells. We find
that NSP1 binds to a precise region on the 18S ribosomal RNA
that resides in the mRNA entry channel of the initiating 40S ribo-
some. This interaction leads to global inhibition of mRNA trans-
lation upon SARS-CoV-2 infection of human cells. Finally, we
find that NSP8 and NSP9 bind to discrete regions on the 7SL
RNA component of the signal recognition particle (SRP) and
interfere with protein trafficking to the cell membrane upon infec-
tion. We show that disruption of each of these essential cellular
functions acts to suppress the type I IFN response to viral infec-
tion. Our results uncover a multipronged strategy utilized by
SARS-CoV-2 to antagonize essential cellular processes and
robustly suppress host immune defenses.
RESULTS
Comprehensive Mapping of SARS-CoV-2 Protein
Binding to Human RNAs
We cloned all 27 of the known SARS-CoV-2 viral proteins into
mammalian expression vectors containing an N-terminal Halo-
Tag (Los et al., 2008; Figure S1A; STAR Methods), expressed
each in HEK293T cells, and exposed them to UV light to cova-
lently crosslink proteins to their bound RNAs. We then lysed
the cells and purified each viral protein using stringent dena-
turing conditions to disrupt any non-covalent associations and
capture those with a UV-mediated interaction (Figure 1A; STAR
Methods). As positive and negative controls, we purified a known
human RNA binding protein (PTBP1) and a metabolic protein
(GAPDH) (Figures S1A–S1E).
We successfully purified 26 of the 27 viral proteins (Figure S1A;
full-length S was not soluble when expressed). We found that 10
viral proteins (NSP1, NSP4, NSP8, NSP9, NSP12, NSP15,
NSP16, ORF3b, N, and E) bind to specific host RNAs (p <
0.001; Figure 1B; Table S1), including 6 structural ncRNAs and
142 mRNAs (Table S1). These include mRNAs involved in protein
translation (e.g., COPS5, EIF1, and RPS12,), protein transport
(ATP6V1G1, SLC25A6, and TOMM20), protein folding (HSPA5,
HSPA6, and HSPA1B), transcriptional regulation (YY1, ID4, and
IER5), and immune response (JUN, AEN, and RACK1) (false dis-
covery rate [FDR] < 0.05; Figures 1B and S1F). Importantly, the
observed interactions are highly specific for each viral protein,
and each protein binds to a precise region within each RNA (Fig-
ures 1C and S1F).
Using these data, we identified several viral proteins that
interact with structural ncRNA components of the spliceosome
(U1 and U2 small nuclear RNA [snRNA]), the ribosome (18S
and 28S rRNA), and the SRP (7SL) (Figure 1B). Because these
molecular machines are essential for three essential steps of
protein production—mRNA splicing, translation, and protein
trafficking—we focused on their interactions with viral proteins
to understand their functions and mechanisms in SARS-CoV-2
pathogenesis.
NSP16 Binds to the Pre-mRNA Recognition Domains of
the U1 and U2 snRNAs
After transcription in the nucleus, nascent pre-mRNAs are spliced
to generate mature mRNAs that are translated into protein.
Splicing ismediated by a complex of ncRNAs and proteins known
as the spliceosome.Specifically, theU1snRNAhybridizes to the50
splice site at the exon-intron junction, and the U2 snRNA
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hybridizes to the branchpoint site in the intron to initiate splicing of
virtually all human mRNAs (Se´raphin et al., 1988).
We identified a highly specific interaction between the NSP16
viral protein and the U1 and U2 snRNAs (Figure 1B). Because U1
and U2 are small RNAs (164 and 188 nt, respectively), we noticed
strong enrichment of NSP16-associated reads across the entire
length of each. To more precisely define the binding sites, we ex-
ploited the well-described tendency of reverse transcriptase to
preferentially terminate when it encounters a UV-crosslinked pro-
tein on RNA (Ko¨nig et al., 2010; Figures 1A and S1D). We deter-
mined that NSP16 binds to the 50 splice site recognition sequence
of U1 (Figures 2A, 2B, S2A, and S2B) and the branchpoint recog-
nition site of U2 (Figures 2C, 2D, S2C, and S2D). These binding
sites are highly specific to NSP16 relative to all of the other viral
and human proteins (Figures 1B, S2A, and 2C). Consistent with
its interaction with U1/U2, we observed that NSP16 localizes in
the nucleus upon SARS-CoV-2 infection (Figures 2E, S2E, and
S2F) and when expressed in human cells (Figure S2G).
NSP16 Disrupts Global mRNA Splicing upon SARS-CoV-
2 Infection
Based on the locations of the NSP16 binding sites relative to the
mRNA recognition domains of the U1/U2 spliceosomal compo-
nents, we hypothesized that NSP16 might disrupt splicing of
newly transcribed genes (Figure 2F). To test this, we co-ex-
pressed NSP16 in human cells along with a splicing reporter
derived from IRF7 (an exon-intron-exon minigene) fused to
GFP (Majumdar et al., 2018). In this system, if the reporter is
spliced, then GFP is made; if not, then translation is terminated
(via a stop codon present in the first intron), and GFP is not pro-
duced (Figure 3A). We observed a more than 3-fold reduction in
GFP levels in the presence of NSP16 compared with a control
human protein (Figures 3B and S3A).
To explore whether NSP16 has a global effect on splicing of
endogenous mRNAs, we measured the splicing ratio of each
gene using nascent RNA sequencing. Specifically, we metaboli-
cally labeled nascent RNAby feeding cells for 20minwith 5-ethy-
nyl uridine (5EU), purified and sequenced 5EU-labeled RNA, and
quantified the proportion of unspliced fragments spanning the 30
splice site of each gene (Figures 3C and S3B). We observed a
global increase in the fraction of unspliced genes in the presence
of NSP16 compared with controls (Figures 3D, S3C, and S3D).
Given that NSP16 is sufficient to suppress global mRNA
splicing, we expect that its expression in SARS-CoV-2-infected
cells would result in a global mRNA splicing deficit. To test this,
we infected human lung epithelial cells (Calu3) with SARS-CoV-2
A B
C
Figure 1. Global RNA Binding Maps of SARS-CoV-2 Proteins
(A) Schematic of our approach.
(B) Enrichment heatmap of each SARS-CoV-2 protein (rows) by significantly enriched 100-nt RNA bins (columns; p < 0.001 and enrichment > 3-fold; STAR
Methods). Shared colored bars indicate multiple bins within the same mRNA. For spacing reasons, the 82 mRNAs bound by N protein are displayed separately.
(C) Examples of sequencing reads over specific mRNAs for viral proteins (red) relative to input RNA coverage (gray) are shown. Coding regions (thick lines) and
untranslated regions (thin lines) are shown for each mRNA.
See also Table S1.
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and measured the splicing levels of newly transcribed mRNAs
compared with a mock-infected control. As expected, we
observed a global increase in the fraction of unspliced tran-
scripts upon SARS-CoV-2 infection, with 90% of measured
genes showing increased intron retention (Figures 3E and S3E).
These results indicate that NSP16 binds to the splice site and
branchpoint sites of U1/U2 to suppress global mRNA splicing in
SARS-CoV-2-infected cells (Figure 3F). AlthoughNSP16 is known
to act as an enzyme that deposits 20-O-methyl modifications on
viral RNAs (Decroly et al., 2011), our results demonstrate that it
also acts as a host virulence factor. Global disruption of mRNA
splicingmay act to decreasehost protein andmRNA levels by trig-
gering nonsense-mediated decay of improperly spliced mRNAs
(Kurosaki et al., 2019). Consistent with this, we observed a strong
global decrease in steady-state mRNA levels (relative to ncRNA
levels) upon SARS-CoV-2 infection (Figure S3F).
A
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Figure 2. NSP16 Binds to U1 and U2 at Their mRNA Recognition Sites
(A) NSP16 enrichment of reverse transcription stop positions across each nucleotide of U1 (red) compared with a control protein (GAPDH, black). The red box
(below the x axis) represents most enriched nucleotide positions (U1, 9–13 nt). The gray-shaded box (overlay) outlines the position of the splice site recognition
sequence.
(B) Left: structure of the pre-catalytic human spliceosome (PDB: 6QX9; Charenton et al., 2019), highlighting the location of NSP16 binding site (red spheres)
relative to U1 (yellow ribbon) and mRNA (purple ribbon). Right: schematic of the structure.
(C) Enrichment across each nucleotide of U2 for NSP16 (red) and GAPDH (black). The red box demarcates most enriched nucleotide positions (U2, 27–34 nt). The
gray-shaded box outlines the location of the branchpoint recognition sequence.
(D) Structure of the pre-catalytic human spliceosome (PDB: 6QX9; Charenton et al., 2019) displaying the NSP16 binding site (red spheres), U2 (orange), and
mRNA (purple).
(E) Mock-infected (top) or SARS-CoV-2 infected (bottom) Vero E6 cells immunostained with a polyclonal antibody to NSP16 (left) or NSP1 (right). Imaris 3D
reconstruction of the DAPI (nucleus) and NSP16 or NSP1 signal are shown for each protein. The signal contained within the 3D nuclear volume (blue) is shown in
yellow and the cytoplasmic signal in purple. Scale bars, 3 mm.
(F) Model: NSP16 binding to U1/U2 can affect mRNA recognition during splicing.
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Inhibition of mRNA Splicing Suppresses the Host IFN
Response to Viral Infection
Because many of the key genes stimulated by IFN are spliced,
we reasoned that mRNA splicing would be critical for a robust
IFN response. To test this, we utilized a reporter line engineered
to express alkaline phosphatase upon IFN signaling (mimicking
an antiviral response gene). This IFN-stimulated gene (ISG) re-
porter line can be stimulated using IFN-b and assayed for re-
porter induction. We observed strong repression of this IFN-
responsive gene upon expression of NSP16 (Figure 3G) and
upon addition of a small molecule that interferes with spliceoso-
mal assembly (Figure S3G). These results demonstrate that one
A B
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Figure 3. NSP16 Suppresses Host mRNA Splicing
(A) Schematic of fluorescence reporter used to assay mRNA splicing.
(B) GFP density plot of HEK293T cells expressing the GFP splicing reporter and either GAPDH (gray) or NSP16 (red).
(C) Schematic of the nascent RNA purification method.
(D) The percentage of unspliced difference for each gene betweenHEK293T cells transfected with GAPDH (gray) or NSP16 (red). The plot represents themerge of
four independent biological replicates; replicates are plotted in Figure S4C.
(E) Violin plot for SARS-CoV-2 infected human lung epithelial cells (MOI = 0.01, 48 h) compared with mock infection. Plots are merges of two biological replicates;
replicates are plotted in Figure S4E.
(F) Model. NSP16 binding to U1 and U2 can reduce overall mRNA and protein levels.
(G) Expression of an IFN-stimulated gene (ISG) reporter upon transfection with GAPDH (gray) or NSP16 (red) after stimulation with IFN-b. Three independent
biological replicates; **p < 0.01.
(H) Example of nascent RNA sequencing at the intron of ISG15 (intron, line; exon, box) upon SARS-CoV-2 (red) or mock (gray) infection.
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Figure 4. NSP1 Binds to 18S Near the mRNA Entry Channel to Suppress Translation
(A) NSP1 enrichment across each nucleotide of 18S. The cyan box indicates the most enriched nucleotides of NSP1 binding (18S, 607–644 nt).
(B) The location of NSP1 binding (cyan spheres) relative to the known structure of 40S (gray) and mRNA (purple ribbon). Right: schematic illustrating structure
(Ameismeier et al., 2018) and how NSP1 binding would block mRNA entry.
(C) Images of HEK293T cells co-expressing the GFP reporter and GAPDH (top) or NSP1 (bottom).
(D) Flow cytometry quantification (mean intensity) of GFP in the presence of GAPDH, NSP8/9, M, or NSP1 proteins. Three independent biological replicates per
condition.
(E) Puromycin incorporation (top) or total actin levels (bottom) measured in Calu3 cells infected with SARS-CoV-2 (MOI = 0.01, 48 h) or a mock-infected control
(left 2 lanes).
(F) The ratio of puromycin signal over total actin signal is plotted for each individual replicate.
(G) Read enrichment on 18S for an independent replicate of NSP1 wild type, NSP1 R124A/K125A mutant, and NSP1 K164A/H165A (DRC) mutant.
(H) Flow cytometry analysis of HEK293T cells transfected with GFP and NSP1DRC mutant (gray), wild-type NSP1, or NSP1 R124A/K125A (cyan).
(legend continued on next page)
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outcome of NSP16-mediated inhibition of mRNA splicing is to
reduce the host cells’ innate immune response to virus recogni-
tion. Consistent with such a role, we observed an increase in
intron retention in multiple IFN-responsive genes (such as
ISG15 and RIG-I) upon SARS-CoV-2 infection (Figures 3H,
S3H, and S3I).
NSP1 Binds to 18S Ribosomal RNA in the mRNA Entry
Channel of the 40S Subunit
When exported to the cytoplasm, spliced mRNA is translated
into protein on the ribosome. Initiation of translation begins
with recognition of the 50 cap by the small 40S subunit (which
scans the mRNA to find the first start codon). We observed
that NSP1 binds exclusively to the 18S ribosomal RNA (Figures
1B and S4A)—the structural RNA component of the 40S ribo-
somal subunit.
Several roles of NSP1 have been reported in SARS-CoV and
MERS-CoV, including roles in viral replication, translational inhi-
bition, transcriptional inhibition, mRNA degradation, and cell cy-
cle arrest (Brockway and Denison, 2005; Kamitani et al., 2009;
Lokugamage et al., 2015; Narayanan et al., 2015). One of the re-
ported roles of NSP1 in SARS-CoV is that it can associate with
the 40S ribosome to inhibit host mRNA translation (Kamitani
et al., 2009; Tanaka et al., 2012), but it remains unknownwhether
this association is due to interaction with the ribosomal RNA,
protein components of the ribosome, or other auxiliary ribosomal
factors. Accordingly, the mechanisms by which NSP1 acts to
suppress protein production remain elusive.
We mapped the location of NSP1 binding to a 37-nt region
corresponding to helix 18 (Figure 4A), adjacent to the mRNA en-
try channel (Simonetti et al., 2020; Figure 4B). The interaction
would position NSP1 to disrupt 40SmRNA scanning and prevent
translation initiation (Figure 4B) and disrupt tRNA recruitment to
the 80S ribosome and block protein production (Figure S4B).
Interestingly, the NSP1 binding site includes the highly
conserved G626 nucleotide, which monitors the minor groove
of the codon-anticodon helix for tRNA binding fidelity (Ogle
et al., 2001). We noticed that the C-terminal region of NSP1
has structural regions similar to SERBP1 (Brown et al., 2018)
and Stm1 (Ben-Shem et al., 2011), two known ribosome inhibi-
tors that bind in the mRNA entry channel to preclude mRNA ac-
cess (Figure S4C). Consistent with this, a recent cryo-EM struc-
ture confirms that NSP1 binds to these same nucleotides of 18S
within the mRNA entry channel (Thoms et al., 2020).
NSP1 Suppresses Global Translation of Host mRNAs
upon SARS-CoV-2 Infection
Given the location of NSP1 binding on the 40S ribosome, we hy-
pothesized that it could suppress global initiation of mRNA trans-
lation. To test this, we performed in vitro translation assays of a
GFP reporter in HeLa cell lysates and found that addition of
NSP1 led to potent inhibition of translation (Figure S4D). We
observed a similar NSP1-mediated translational repression when
weco-expressedNSP1andaGFP reporter gene inHEK293Tcells
(Figures 4C and 4D). In contrast, we did not observe this inhibition
when we expressed other SARS-CoV-2 proteins (NSP8, NSP9, or
M) or human proteins (GAPDH) (Figure 4D).
To determine whether NSP1 leads to translational inhibition of
endogenous proteins in human cells, we used a technique called
surface sensing of translation (SUnSET) to measure global pro-
tein production levels (Schmidt et al., 2009). In this assay, trans-
lational activity is measured by the level of puromycin incorpora-
tion into elongating polypeptides (Figure S4E). We observed a
strong reduction in the level of global puromycin integration in
cells expressing NSP1 comparedwith cells expressing GFP (Fig-
ures S4F and S4G).
Because NSP1 expression is sufficient to suppress global
mRNA translation in human cells, we hypothesized that SARS-
CoV-2 infection would also suppress global translation. To test
this, we infected a human lung epithelial (Calu3) or monkey kid-
ney (Vero) cell line with SARS-CoV-2 andmeasured nascent pro-
tein synthesis levels using SUnSET. We observed a strong
reduction of global puromycin integration upon SARS-CoV-2
infection in both cell types (Figures 4E, 4F, S4H, and S4I).
To explore whether NSP1 binding to 18S rRNA is critical for
translational repression, we generated a mutant NSP1 in which
two positively charged amino acids (K164 and H165) in the C-ter-
minal domain were replaced with alanine residues (Figure S4C;
Narayanan et al., 2008).Weobserved complete lossof in vivocon-
tacts with 18S (Figure 4G); because thismutant disrupts ribosome
contact, we refer to it as NSP1DRC. We co-expressed GFP and
NSP1DRC in HEK293T cells and found that the mutant fails to
inhibit translation (Figures 4H and S4J). In contrast, mutations to
the positively charged amino acids at positions 124/125 do not
affect 18S binding (Figure 4G) or the ability to inhibit translation
(Figure 4H).
These results demonstrate that NSP1 binds in the mRNA entry
channel of the ribosome and that this interaction is required for
translational inhibition of host mRNAs upon SARS-CoV-2
infection.
NSP1-Mediated Translational Inhibition Suppresses the
Host IFN Response
We explored whether NSP1 binding to 18S rRNA suppresses the
ability of cells to respond to IFN-b stimulation upon viral infec-
tion. We transfected ISG reporter cells with NSP1, stimulated
with IFN-b, and observed robust repression of the IFN-respon-
sive gene (>6-fold; Figure 4I). To confirm that this NSP1-medi-
ated repression occurs in human cells upon activation of dou-
ble-stranded RNA (dsRNA)-sensing pathways typically
triggered by viral infection, we treated a human lung epithelial
cell line (A549) with poly(I:C), a molecule that is structurally
similar to dsRNA and known to induce an antiviral innate immune
response (Alexopoulou et al., 2001; Kato et al., 2006) (Fig-
ure S4K). We observed marked downregulation of IFN-b protein
and endogenous IFN-b-responsive mRNAs in the presence of
NSP1 but not in the presence of NSP1DRC (Figures S4L and
S4M). These results demonstrate that NSP1, through its
(I) Quantification of the IFN-b response in the presence of GAPDH (gray) or NSP1 (cyan).
(J) Schematic of how NSP1 acts to suppress mRNA translation.
Error bars represent standard deviation across biological replicates, and dots represent individual values for each replicate; *p < 0.05 and **p < 0.01.
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interaction with 18S rRNA, suppresses the innate immune
response to virus recognition (Figure 4J).
The Viral 50 Leader Protects mRNA fromNSP1-Mediated
Translational Inhibition
Because NSP1 blocking the mRNA entry channel would affect
host and viral mRNA translation, we explored how translation
of viral mRNAs is protected from NSP1-mediated translational
inhibition. Many viruses contain 50 untranslated regions that
regulate viral gene expression and translation (Gaglia et al.,
2012); all SARS-CoV-2-encoded subgenomic RNAs contain a
common 50 leader sequence that is added during negative-
strand synthesis (Kim et al., 2020b). We explored whether the
leader sequence protects viral mRNAs from translational inhibi-
tion by fusing the viral leader sequence to the 50 end of GFP or
mCherry reporter genes (Figure S5A). We found that NSP1 fails
to suppress translation of these leader-containing mRNAs (Fig-
ures 5A, 5B, and S5B). We dissected the leader sequence and
found that the first stem loop (SL1) is sufficient to prevent trans-
lational suppression upon NSP1 expression (Figure 5C) or
SARS-CoV-2 infection (Figure 5D).
We considered three models for how the leader could protect
viralmRNAs: (1) it couldcompetewith the ribosome forNSP1bind-
ing, (2) it could directly recruit free ribosomes, or (3) NSP1 could
bind to the leader independentof its ribosome interactiontoalloste-
ricallymodulate theNSP1-ribosome interaction.We reasoned that
if the leader competes for NSP1 binding or directly recruits free ri-
bosomes, then the presenceof SL1 should be sufficient for protec-
tion, regardless of its precise position in the 50 UTR. In contrast, if
the leader allosterically modulates ribosome binding, then the
spacing between the 50 cap (which is bound to NSP1-40S) and
SL1 would be critical for protection. To distinguish between these
models, we swapped the location of SL1 and SL2 in the 50 leader
or inserted 5 nt between the 50 cap andSL1 (FigureS5C) and found
that both mutants ablate protection (Figures 5E and S5D).
These results indicate that an mRNA requires the 50 leader to
be precisely positioned relative to the NSP1-bound 40S ribo-
some to enable translational initiation (Figure 5F). Although
many aspects of this allosteric model remain to be explored, it
would explain how leader-mediated protection can occur on
an mRNA only when present in cis. Moreover, this model sug-
gests that NSP1 might also act to further increase viral mRNA
translation by actively recruiting the ribosome to its ownmRNAs.
Consistent with this, we observed a consistent, 20% increase
in translation of leader-containing reporter levels upon viral infec-
tion (Figure 5D) or expression of NSP1 (Figure S5E).
A B C
D E F
Figure 5. The 50 Viral Leader Protects mRNA from NSP1-Mediated Translational Inhibition
(A) Images of cells co-transfected with NSP1 and mCherry alone ( leader, top) or mCherry fused to the SARS-CoV-2 leader (+ leader, bottom).
(B) GFP (green) or mCherry (red) levels when fused to the viral leader (+ leader, right) or lacking the viral leader ( leader, left).
(C) GFP reporter with no leader (left), full leader (center), or stem loop 1 (SL1) upon NSP1 expression.
(D) Calu3 cells expressing SL1 fused toGFP. Cells weremock or SARS-CoV-2 infected (MOI = 0.1), andGFP expression wasmeasured 24 h after infection by flow
cytometry.
(E) GFP reporter containing SL1 (left), a swap of SL2 and SL1 (SL2-SL1), insertion of 5 nt between the 50 end and SL1 (+5 nt-SL1), or no leader. GFP protein level
was measured for each condition upon expression of NSP1.
(F) Proposed model of how NSP1 binding to the viral leader can allosterically modulate NSP1 structure to protect mRNAs in cis.
Error bars represent standard deviation across biological replicates, and dots represent individual replicate values; *p < 0.05 and **p < 0.01.
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NSP8 and NSP9 Bind to the 7SL RNA Component of SRP
Upon engaging the start codon in an mRNA, the 60S subunit of
the ribosome is recruited to form the 80S ribosome, which trans-
lates mRNA. SRP is a universally conserved complex that binds
to the 80S ribosome and acts to co-translationally scan the
nascent peptide to identify hydrophobic signal peptides present
in integral membrane proteins and proteins secreted from the
plasma membrane (Akopian et al., 2013). When these are identi-
fied, SRP triggers ribosome translocation to the endoplasmic re-
ticulum (ER) to ensure proper folding and trafficking of these pro-
teins to the cell membrane (Akopian et al., 2013).
We identified two viral proteins, NSP8 and NSP9, that bind at
distinct and highly specific regions in the S domain of the 7SL
RNA scaffold of SRP (Figures 6A and S6A). NSP8 interacts
with 7SL in the region bound by SRP54 (the protein responsible
for signal peptide recognition, SRP-receptor binding, and ribo-
some translocation; Akopian et al., 2013; Holtkamp et al.,
2012; Figure 6B). NSP9 binds to 7SL in the region that is bound
by the SRP19 protein (Figure 6B), which is required for proper
folding and assembly of the SRP (including proper loading of
SRP54; Akopian et al., 2013).
Because SRP scans nascent peptides co-translationally, we
were intrigued to find that NSP8 also forms a highly specific
interaction with 28S rRNA (the structural component of the 60S
subunit) (Figures 6C and S6B). The binding site on 28S rRNA cor-
responds to the largest human-specific expansion segment in
the ribosome, referred to as ES27 (Parker et al., 2018). ES27 is
highly dynamic and, thus, has not been resolved in most ribo-
some structures (Zhang et al., 2014). However, when engaged
by specific factors, ES27 can become ordered and has been
A
C
D
B
Figure 6. NSP8 and NSP9 Bind to 7SL RNA of the SRP
(A) Enrichment of reverse transcription stop positions across each nucleotide of 7SL is shown for NSP8 (blue) and NSP9 (red). Red (7SL, 142–143 nt; 7SL, 149–
151 nt) and blue (7SL, 193–194 nt) boxes demarcate the most enriched nucleotide positions.
(B) The locations of the NSP8 (blue spheres) and NSP9 (red spheres) binding sites on the S domain of 7SL (yellow ribbon) structure relative to SRP54 and SRP19
(gray) (PDB: 1MFQ; Kuglstatter et al., 2002). Right: schematic of the structure and model of how NSP8/9 binding to 7SL could affect SRP protein binding.
(C) Read enrichment across each nucleotide of 28S for NSP8 (blue). The black box indicates the location of the ES27 expansion sequence (28S, 2,889–3,551 nt).
The blue box indicates the most enriched nucleotide position on 28S rRNA (28S, 3,017–3,529 nt).
(D) The locations of the NSP8 (blue) and NSP9 (red) binding sites relative to the structure of the SRP-ribosome complex (PDB: 3JAJ; Voorhees and Hegde, 2015)
superimposed on the structure of the ES27 region of 28S (Ebp1-ribosome complex; PDB: 6SXO; Wild et al., 2020). The observed NSP8 binding site in the ES27
region of 28S (gray) is demarcated in blue, and the NSP8 (blue) and NSP9 (red) binding sites on 7SL (yellow) are highlighted. Right: schematic illustrating the
interaction between the ribosome and SRP.
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shown recently to be capable of interacting with the ribosome
exit tunnel adjacent to the 60S binding site of SRP (Figures 6D
and S6C; Wild et al., 2020).
These observations suggest that NSP8 and NSP9 bind to the
co-translational SRP complex. Consistent with this, we find that
NSP8 and NSP9 localize broadly throughout the cytoplasm
when expressed in human cells (Figure S6D) or upon SARS-
CoV-2 infection (Figures S6E and S6F).
NSP8 and NSP9 Suppress Protein Integration into the
Cell Membrane
Because NSP8 and NSP9 binding on 7SL are positioned to
disrupt SRP function, we hypothesized that they may alter trans-
location of secreted and integral membrane proteins
(Figure S7A).
To test this, we expressed an SRP-dependent membrane pro-
tein (nerve growth factor receptor [NGFR]; Izon et al., 2001) fused
via an internal ribosome entry site (IRES) to a non-membrane
GFP (Figure S7F). In this system, when a perturbation specifically
affects membrane protein levels, we expect to see a decrease in
the ratio of membrane to non-membrane protein levels. To
ensure that the NGFR reporter accurately reports SRP function,
we treated HEK293T cells with small interfering RNAs (siRNAs)
against SRP54 or SRP19 and found that both lead to a dramatic
reduction of the NGFR membrane protein relative to the non-
membrane GFP protein (Figure S7B). Similarly, we found that
expression of NSP8 andNSP9 (alone or together) led to a striking
reduction in expression of NGFR relative to GFP (Figure 7A).
Expression of control proteins did not specifically affect NGFR
levels (Figures 7A and S7B).
To determine whether there is a global effect on membrane
protein levels, we utilized the SUnSET method to measure puro-
mycin levels in membrane proteins using flow cytometry (STAR
Methods). We confirmed that disruption of SRP leads to a global
reduction in puromycin levels in the cell membrane (Figure S7C).
We observed a comparable global reduction of puromycin-
labeled membrane proteins upon expression of NSP8 or NSP9
individually or together but not with control proteins (Figures
7B and S7C).
SARS-CoV-2 Infection Suppresses Protein Integration
into the Cell Membrane
Because NSP8 and NSP9 are each sufficient to suppress protein
integration into the cell membrane, we anticipated that SARS-
CoV-2 infection would lead to similar suppression. However,
determining whether SARS-CoV-2 infection specifically affects
membrane protein expression is confounded by the fact that
NSP1 inhibits translation of membrane and non-membrane pro-
teins upon infection.
To address this, we co-expressed a membrane protein re-
porter (NGFR) containing the 50 viral leader along with a non-
membrane GFP reporter containing the viral leader. Upon viral
infection, we observed a strong reduction in membrane protein
levels (Figure 7C) but no reduction in non-membrane GFP levels
(Figure 5D). To ensure that these effects are specific to SARS-
CoV-2-infected cells, we separated individual cells in the in-
fected population into those expressing the viral S protein (S+)
and those not expressing the protein (S). We found that the
shift in membrane protein levels only occurred in S+ cells (Fig-
ure 7D), whereas the S- population resembled themock-infected
samples (Figure 7C). We observed a strong relationship between
the level of S protein, likely reflecting the amount of viral replica-
tion in each cell, and the level of membrane protein suppression
(Figure 7C). We observed this membrane protein-specific
decrease upon infection of human lung epithelial cells (Calu3;
Figure S7D) and monkey kidney cells (Vero; Figures 7C and 7D).
These results demonstrate that NSP8 and NSP9 bind to 7SL to
disrupt SRP function and suppress membrane protein trafficking
in SARS-CoV-2-infected cells. Although NSP8 and NSP9 are
thought to be components of the virus replication machinery
(Sutton et al., 2004), our results indicate that they play an addi-
tional role as host virulence factors. Because viral membrane
proteins also require trafficking to the ER, viral disruption of
SRP might also negatively impact virus propagation, unless viral
proteins are trafficked in an SRP-independent manner (Fig-
ure S7E) or if NSP8/9 selectively affects host (but not viral) pro-
tein trafficking.
Viral Disruption of Protein Trafficking Suppresses the
IFN Response
Next we explored how disruption of SRPmight be advantageous
for virus propagation. Because secretion of IFN and other cyto-
kines is dependent on the SRP complex for secretion (Fig-
ure S7F), a central component of the IFN response is dependent
on SRP. Accordingly, we hypothesized that NSP8/9-mediated
viral suppression of SRPwould act to suppress the IFN response
upon infection. To test this, we co-expressed NSP8 and NSP9
and observed a significant reduction in the IFN response relative
to a control protein (Figure S7G).
These results suggest that SARS-CoV-2-mediated suppres-
sion of SRP-dependent protein secretion enables suppression
of host immune defenses (Figure 7E). Interestingly, many pro-
teins involved in anti-viral immunity, including most cytokines
and MHC class I, are membrane anchored or secreted and are
known to use the SRP pathway for transport (Vermeire et al.,
2014; Figure S7F), suggesting that there may be other effects
of SRP pathway inhibition on SARS-CoV-2 pathogenesis.
DISCUSSION
We identified several pathogenic functions of SARS-CoV-2 in hu-
man cells, including global inhibition of host mRNA splicing, pro-
tein translation, and membrane protein trafficking, and described
themolecularmechanismsbywhich the virus acts todisrupt these
essential cell processes. Interestingly, all of the viral proteins
involved (NSP1, NSP8, NSP9, and NSP16) are produced in the
first stage of the virus life cycle prior to generation of dsRNA prod-
ucts during virus genome replication. Because dsRNA is detected
by host immune sensors and triggers the type I IFN response,
disruption of these cellular processes allows the virus to replicate
its genome while minimizing the host innate immune response.
Disruption of these three non-overlapping steps of protein pro-
duction may represent a multi-prongedmechanism that synergis-
tically acts tosuppress thehostantiviral response (Figure7F).Spe-
cifically, the IFN response is usually boostedmore than 1,000-fold
upon virus detection (through amplification and feedback;
ll
10 Cell 183, 1–15, November 25, 2020
Please cite this article in press as: Banerjee et al., SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host De-
fenses, Cell (2020), https://doi.org/10.1016/j.cell.2020.10.004
Article
A B E
C D
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Figure 7. NSP8 and NSP9 Inhibit Membrane and Secretory Protein Trafficking
(A) Quantification of HEK293T cells transfected with plasmids co-expressing GFP-tagged NSPs and the NGFRmembrane protein. Plotted is the ratio of NGFR to
GFP levels for each condition.
(B) The ratio of puromycin-containing proteins at the cell membrane normalized to GFP expression for each condition.
(C) Quantification of two mRNA reporters containing SL1 fused to GFP (leader-GFP) or NGFR (leader-NGFR) in Vero cells infected with SARS-CoV-2 or mock
infected for 24 h (MOI, 0.1). Plotted is the ratio of leader-NGFR to leader-GFP, binned by increasing amounts of S protein.
(D) Density plot for leader-NGFR to leader-GFP ratios in virally infected Vero cells or mock-treated controls. Replicate conditions were merged for display.
(E) Model of how NSP8/9 act to suppress SRP-dependent protein trafficking upon viral infection.
(F) A model of how SARS-CoV-2 suppresses host immune responses through multi-pronged inhibition of core cellular functions. Cellular mechanisms are shown
in gray and viral mechanisms in red.
Error bars represent standard deviation across independent biological replicates, and dots represent individual values for each replicate; *p < 0.05 and **p < 0.01.
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Figure S4K), but each individualmechanism affects IFN levels5-
to 10-fold. Accordingly, if each independent mechanism moder-
ately affects IFN levels, the three together may be able to achieve
dramatic suppression of IFN (103 = 1,000-fold). Thismulti-pronged
mechanism may explain the molecular basis of the potent sup-
pression of IFN observed in patients with severe COVID-19.
IFN is emerging not only as a determinant of disease severity
but also as a potential treatment option (Zhou et al., 2020). Our
work identifies several therapeutic opportunities for boosting
IFN levels upon SARS-CoV-2 infection. For example, disrupting
the interaction between NSP1 and 18S rRNA could allow cells to
detect and respond to viral infection. Becausemany small-mole-
cule drugs target ribosomal RNAs (Liaud et al., 2019), it may be
possible to develop drugs to block NSP1-18S and other interac-
tions. Additionally, disrupting the 50 viral leader may be a potent
antivirus strategy because it is critical for translation of all viral
proteins. Because SL1 is a structured RNA, it may be possible
to design small molecules that specifically bind this structure
to suppress viral protein production (Hermann, 2016).
Viral suppression of these cellular functions is not exclusive to
the IFN response and also affects other spliced, translated,
secreted, and membrane proteins. Many proteins involved in
anti-viral immunity are spliced and/or membrane anchored or
secreted; for example, MHC class I, critical for antigen presenta-
tion to CD8 T cells at the cell surface of infected cells (Hansen and
Bouvier, 2009). By antagonizing membrane trafficking, SARS-
CoV-2 may prevent viral antigens from being presented on MHC
and allow infected cells to escape T cell recognition and clear-
ance. In this way, interference with these essential cellular pro-
cesses might further aid SARS-CoV-2 to evade the host immune
response.
More generally, we expect that insights gained from the
SARS-CoV-2 protein-RNA binding maps will be critical for
exploring additional viral mechanisms. Specifically, we identified
many other interactions, including highly specific interactions
with mRNAs. For example, NSP12 binds to the JUN mRNA (Fig-
ure S1E), which encodes the critical immune transcription factor
c-Jun, which is activated in response to multiple cytokines and
immune signaling pathways (Weston and Davis, 2007). We also
identified an interaction between NSP9 and the start codon of
the mRNA that encodes COPS5 (Figure 1C), the enzymatic sub-
unit of the COP9 signalosome complex, which regulates protein
homeostasis (Cope and Deshaies, 2003), suggesting that it
might disrupt its translation. Interestingly, COPS5 (also known
as JAB1) is known to bind and stabilize c-Jun protein (Claret
et al., 1996), and several viruses are known to disrupt this protein
(Lungu et al., 2008; Oh et al., 2006; Tanaka et al., 2006). Although
it remains unknown what, if any, role these interactions have in
virus-infected cells, the specificity suggests that they may pro-
vide a selective advantage for virus propagation.
Our results demonstrate that global mapping of RNA binding
by viral proteins could enable rapid characterization of mecha-
nisms of emerging pathogenic RNA viruses.
Limitations of Study
Several limitations of our current studywill need to be explored in
future work. (1) Our mapping experiments were performed with
uninfected human cells expressing tagged viral proteins.
Accordingly, it remains possible that our mapsmay not fully cap-
ture all of the interactions that occur when human cells are in-
fected, such as interactions that occur with virus-induced
RNAs, in specific viral compartments, or that require multiple
viral proteins. (2) Although we characterized the functional and
mechanistic roles of several viral proteins and structural
ncRNAs, we did not explore the roles of viral protein interactions
with mRNAs. (3) How the virus disrupts fundamental cellular pro-
cesses while maintaining its own production is still largely unde-
fined. Although we showed that the 50 leader is sufficient to
relieve translational inhibition byNSP1, we still do not fully under-
stand how this protection occurs and, specifically, how NSP1
might interact with the viral leader or allosterically modulate ribo-
some binding. Similarly, viral membrane proteins are dependent
on trafficking to the ER, and how NSP8/9 might selectively affect
ER translocation of host but not viral proteins remains to be
explored. (4) Although we showed that viral disruption of these
essential cellular functions can suppress IFN, other roles of
host cell shutdown in viral pathogenesis and in suppressing
other aspects of antiviral immunity, including possible roles in
adaptive immune responses, have not been explored.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-NSP1 sheep polyclonal antibody MRC-University of GlasgowCentre for Virus
Research (CVR)
N/A
Anti-NSP8 sheep polyclonal antibody MRC CVR N/A
Anti-NSP9 sheep polyclonal antibody MRC CVR N/A
Anti-NSP16 sheep polyclonal antibody MRC CVR N/A
Anti-Actin antibody Developmental Studies Hybridoma
Bank JLA20
Cat. # 528068
PE-labeled anti-NGFR antibody Biolegend Cat. # 345105
Rabbit anti-SARS-Cov-2 Spike Antibody Sino Cat. # 40591-T62-100
PacBlue-labeled streptavidin Thermo Cat. # S1222
PE-labeled anti-Rabbit Thermo Cat. # P-2771MP
anti-puromycin antibody EMD Millipore Cat. # MABE343 Clone 12D10
Bacterial and Virus Strains
2019-nCoV/USA_USA WA1/2020 (WA1) WRCEVA N/A
Chemicals, Peptides, and Recombinant Proteins
HMW poly(I:C) Invivogen Cat. # tlrl-pic
IFN-beta R&D Systems Cat. # 8499-IF-010/CF
HaloTag Alexa Fluor 660 Ligand Promega Cat. # G8471
Halolink Resin Promega Cat. # G1915
Biotin Picolyl Azide Click Chemistry Tools Cat. # 1167-25
5 ethyl uridine Jena Bioscience Cat. # CLK-N002-CSTM
Critical Commercial Assays
QUANTI-Blue Invivogen Cat. # rep-qbs
1-Step Human Coupled IVT-DNA Thermo Cat. # 88882
Rabbit Reticulocyte Lysate System Promega Cat. # L4960
TransIT-mRNA Transfection Kit Mirus Cat. # MIR2225
HiScribe T7 ARCA mRNA Kit NEB Cat. # E2060S
Deposited Data
SARS-CoV-2 Protein Capture and RNA
Sequencing
NCBI Short Read Archive (SRA) Accession # PRJNA665692
Nascent and total RNA-Seq data NCBI Short Read Archive (SRA) Accession # PRJNA665581
Pre-catalytic human spliceosome structure Charenton et al., 2019 PDB: 6QX9
Structure of S domain of 7SL Kuglstatter et al., 2002 PDB: 1MFQ
Structure of SRP-Ribosome Complex Voorhees and Hegde, 2015 PDB: 3JAJ
Structure of Ebp1-ribosome complex Wild et al., 2020 PDB: 6SXO
Structure of the human 40S ribosome Ameismeier et al., 2018 PDB: 6G5H
Structure of mRNA path through ribosome Simonetti et al., 2020 PDB: 6YAL
Structure of SERBP1 Brown et al., 2018 PDB: 6MTE
Structure of Stm1 Ben-Shem et al., 2011 PDB: 4V88
APPRIS database Rodriguez et al., 2013 N/A
Experimental Models: Cell Lines
HEK293T ATCC Cat. # CRL-3216
Vero E6 J.L. Whitton and Michele Bouloy N/A
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
HEK-Blue-ISG Invivogen Cat. # hkb-igs-1
A549 ATCC Cat. # CCL-185
Calu3 ATCC Cat. # HTB-55
Oligonucleotides
Primers for In-vitro transcription See Table S4 N/A
Primers used for qPCR See Table S2 N/A
siRNA targeting SRP19 Dharmacon L-019729-01-0005
siRNA targeting SRP54 Dharmacon L-005122-01-0005
Recombinant DNA
Template used in mRNA generation See Table S5 N/A
NSP1 Kim et al., 2020a RRID: Addgene_141255
NSP2 Kim et al., 2020a RRID: Addgene_141256
PLPRO (NSP3) Kim et al., 2020a RRID: Addgene_141257
NSP4 Kim et al., 2020a RRID: Addgene_141258
NSP5 Kim et al., 2020a RRID: Addgene_141259
NSP6 Kim et al., 2020a RRID: Addgene_141260
NSP7 Kim et al., 2020a RRID: Addgene_141261
NSP8 Kim et al., 2020a RRID: Addgene_141262
NSP9 Kim et al., 2020a RRID: Addgene_141263
NSP10 Kim et al., 2020a RRID: Addgene_141264
NSP11 Kim et al., 2020a RRID: Addgene_151991
RNA-pol (NSP12) Kim et al., 2020a RRID: Addgene_141265
Heli (NSP13) Kim et al., 2020a RRID: Addgene_141266
NSP14 Kim et al., 2020a RRID: Addgene_141267
NSP15 Kim et al., 2020a RRID: Addgene_141268
NSP16 Kim et al., 2020a RRID: Addgene_141269
ORF3A Kim et al., 2020a RRID: Addgene_141271
ORF3B Kim et al., 2020a RRID: Addgene_141272
E Kim et al., 2020a RRID: Addgene_141273
M Kim et al., 2020a RRID: Addgene_141274
ORF6 Kim et al., 2020a RRID: Addgene_141275
ORF7A Kim et al., 2020a RRID: Addgene_141276
ORF7B Kim et al., 2020a RRID: Addgene_141277
ORF8 Kim et al., 2020a RRID: Addgene_141278
ORF9B Kim et al., 2020a RRID: Addgene_141280
N Kim et al., 2020a RRID: Addgene_149330
NSP11 (pGBW-m4133457) Ginko Bioworks RRID: Addgene_151991
pB-TAG-ERN Kim et al., 2016 RRID: Addgene_80476
NGFR Izon et al., 2001 RRID: Addgene_27489
Software and Algorithms
Imaris Oxford Instruments, Imaris https://imaris.oxinst.com
Transform-restrained Rosetta Algorithm Yang et al., 2020 https://yanglab.nankai.edu.cn/trRosetta/
Pymol Schrodinger https://pymol.org/2/
Modeler version 9.24 Webb and Sali, 2016 https://salilab.org/modeller/manual/
FloJo analysis software FlowJo, LLC. https://www.flowjo.com/solutions/flowjo
MAFFTT (v7.407) Rozewicki et al., 2019 https://mafft.cbrc.jp/alignment/server/
Geneious Geneious https://www.geneious.com
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for reagents and resources should be directed to and will be fulfilled by the Lead Contact, Mitchell
Guttman (mguttman@caltech.edu).
Materials Availability
All constructs and plasmids generated in this study will be made available on request sent to the Lead Contact with a completed
Materials Transfer Agreement.
Data and Code Availability
All datasets generated during this study are available at NCBI Short Read Archive: Bioproject PRJNA665692 (viral protein purifica-
tions) and PRJNA665581 (nascent and total RNA-Seq). Table S1 is available at Mendeley data archive, Mendeley Data: http://dx.doi.
org/10.17632/zg7wp4xd5v.1
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines used in this study
We used the following cell lines in this study: (i) HEK293T, a female human embryonic kidney cell line obtained from ATCC. (ii) HEK-
Blue ISG, Interferon regulatory factor (IRF)-inducible Secreted Alkaline Phosphatase (SEAP) reporter HEK293 cells of female origin
(Invivogen). (iii) A549, a male human lung epithelial cell line obtained from ATCC. (iii) Calu3, a male human lung epithelial cell line ob-
tained from ATCC, (iv) Vero E6, a female African green monkey kidney cell line, kindly provided by J.L. Whitton and Michele Bouloy.
Cell culture conditions
A549s, HEK293T cells and derivatives were cultured in complete media consisting of DMEM (GIBCO, Thermo Fisher Scientific) sup-
plemented with 10%FBS (SeradigmPremiumGrade HI FBS, VWR), 1X penicillin-streptomycin (GIBCO, Thermo Fisher Scientific), 1X
MEM non-essential amino acids (GIBCO, Thermo Fisher Scientific), 1 mM sodium pyruvate (GIBCO, Thermo Fisher Scientific) and
maintained at 37C under 5% CO2. For maintenance, 800,000 cells were seeded into 10 mL of complete media every 3-4 days in
10 cm dishes. Vero E6 cells were maintained in complete DMEM (Thermo Fisher Scientific, 11965–092) containing 10% fetal bovine
serum (FBS) (Thermo Fisher Scientific, 16140–071), 1%HEPES Buffer Solution (Thermo Fisher Scientific, 15630–130), and 1% peni-
cillin-streptomycin (Thermo Fisher Scientific, 15140–122). Calu3 cells were maintained in Eagles’s Minimal Essential Medium (ATCC)
containing 10% FBS and 1% penicillin-streptomycin purchased from Thermo Fisher Scientific. All cell lines were maintained at 37C
under 5% CO2. Cells were grown in a humidified incubator at 37
C with 5% CO2.
SARS-CoV-2 Viral Infection strains and conditions
All experiments using infectious SARS-CoV-2 conducted at the UVM BSL-3 facility were performed under an approved Institutional
Biosafety protocol. SARS-CoV-2 strain 2019-nCoV/USA_USAWA1/2020 (WA1) was generously provided by Kenneth Plante and the
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at the University of TexasMedical Branch and propagated
in Vero E6 cells. Viral infections were performed at the indicated multiplicity of infection in a low volume of normal cellular mainte-
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Integrative Genomics Viewer Robinson et al., 2011 http://software.broadinstitute.org/
software/igv/
Morpheus Broad Institute https://software.broadinstitute.org/
morpheus/
Molecular Signatures Database Gene
Ontology Biological Processes and
Reactome
Liberzon et al., 2015 https://www.gsea-msigdb.org/gsea/
msigdb
Trimmomatic Bolger et al., 2014 https://github.com/timflutre/trimmomatic
STAR Aligner Dobin et al., 2013 https://github.com/alexdobin/STAR
PICARD ‘‘Picard Toolkit.’’ 2019. Broad Institute,
GitHub Repository.
https://broadinstitute.github.io/picard/
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
ll
e3 Cell 183, 1–15.e1–e10, November 25, 2020
Please cite this article in press as: Banerjee et al., SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host De-
fenses, Cell (2020), https://doi.org/10.1016/j.cell.2020.10.004
Article
nance media containing 2% FBS for one hour at 37C, inoculum was removed and then overlaid in the respective cellular mainte-
nance media containing 10% FBS for the indicated time periods. Experiments performed to visualize the location of viral NSP pro-
teins (and associated antibody validation) were performed in a Containment Level 3 facility at the MRC-University of Glasgow Centre
for Virus Research using SARS-CoV-2 strain England-02 (from Public Health England [now called National Institute for Health Pro-
tection], GISAID: EPI_ISL_407073) using a MOI of 0.1 or 1 (as indicated).
METHOD DETAILS
Generation of RNA binding maps
Cloning of expression constructs
SARS-CoV-2 protein constructs (with the exception of Nsp11) were a gift from Fritz Roth (see Table S3 for Addgene information) (Kim
et al., 2020a) and were LR-cloned (Invitrogen Gateway Cloning, Thermo Fisher Scientific) into mammalian expression destination
vector pCAG-Halo-TEV-DEST-V5-IRES-puroR. Note that following LR cloning, proteins were not V5-tagged because all entry clones
contained stop codons. For NSP11, an entry clone was generated by BP cloning (Invitrogen Gateway Cloning, Thermo Fisher Sci-
entific) a PCR amplicon (primers: ggGGACAAGTTTGTACAAAAAAGCAGGCTTTtcagctgatgcacaatcgtttttaaacgg and gGGGAC-
CACTTTGTACAAGAAAGCTGGGTTttacaccgcaaacccgtttaaaaacgattg; template: pGBW-m4133457 a gift from Ginkgo Bioworks)
into pDONR221.
Expression and lysis
For each viral protein capture, we transfected 10 mg of these expression vectors into HEK293T cells grown on a 15cm dish using BioT
transfection reagent (Bioland) according to manufacturer’s recommendations. 24-48 hours post-transfection, cells were washed
once with PBS and then crosslinked on ice using 0.25 J cm2 (UV2.5k) of UV at 254 nm in a Spectrolinker UV Crosslinker. Cells
were then scraped from culture dishes, washed once with PBS, pelleted by centrifugation at 1,000 3 g for 5 min, and flash-frozen
in liquid nitrogen for storage at –80C.We lysed batches of 5million cells by completely resuspending frozen cell pellets in 1mL of ice
cold lysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% Sodium Deoxycholate) supplemented with 1X
Protease Inhibitor Cocktail (Promega), 200 U of Ribolock (Thermo Fisher Scientific), 20 U Turbo DNase (Ambion), and 1XManganese/
CalciumMix (0.5mMCaCl2, 2.5mMMnCl2). Samples were incubated on ice for 10minutes to allow lysis to proceed. The lysates were
then incubated at 37C for 10 minutes at 700 rpm shaking on a Thermomixer (Eppendorf). Lysates were cleared by centrifugation at
15,000 3 g for 2 minutes. The supernatant was collected and kept on ice until bound to the HaloLink Resin (Promega). Of the 1mL
lysis volume, 50uL was set aside for input, 20uL used for protein expression confirmation, and the rest for capture on HaloLink Resin
as described below.
Expression confirmation
Lysis supernatant set aside for expression testing was combined with 1.5 mL of 1:60 diluted HaloTag Alexa Fluor 660 Ligand
(Promega) and incubated at room temperature for 20 min in the dark. To stop the reaction, we added LDS loading buffer to 1X final
concentration (4 mL 10X Bolt reducing agent, 10 mL 4X NuPAGE LDS Sample Buffer, 4 mL H2O), denatured the mixture at 90C for
10 min and ran on a Bolt 4%–12%Bis-Tris Plus Gel (all products Thermo Fisher Scientific). Resolved gel was imaged directly on a Li-
Cor Odyssey CLx.
Protein capture
We used 200 mL of 25% HaloLink Resin slurry (50 mL of HaloLink Resin total) per 5 million cells. Resin was washed three times with
2 mL of 1X PBS-T (1x PBS + 0.1% Triton X-100) and incubated in 1X Blocking Buffer (50 mM HEPES, pH 7.4, 100 mg/mL BSA) for
20 minutes at room temperature with continuous rotation. After the incubation, resin was washed three times with 1X PBS-T. The
cleared lysate wasmixedwith 50 mL of HaloLink Resin and incubated at 4C for 3-16 hr with continuous rotation. The captured protein
bound to resin waswashed three timeswith lysis buffer at room temperature and then washed three times at 90C for 3minutes while
shaking on a Thermomixer at 1200 rpm with each of the following buffers: 1X NLS buffer (1xPBS, 2% NLS, 10 mM EDTA), High Salt
Buffer (50 mMHEPES, pH 7.4, 0.1%NP-40, 1MNaCl), 8MUrea Buffer (50 mMHEPES, pH 7.5, 0.1%NP-40, 8 MUrea), Tween buffer
(50mMHEPES, pH 7.4, 0.1%Tween 20) and TEV buffer (50mMHEPES, pH 7.4, 1mMEDTA, 0.1%NP-40). The extended incubation
of the bound RNA with the wash buffers leads to chemical fragmentation of the RNA yielding sizes that are suitable for RNA library
preparation and binding site resolution. Between each wash, samples were centrifuged at 1,000 3 g for 30 s and supernatant was
removed. After the last wash, samples were centrifuged at 7,500 3 g for 30 s and supernatant was discarded. For elution, the resin
was resuspended in 100 mL of NLS Buffer and 10 mL of Proteinase K (NEB) and the sample was incubated at 50C for 30minuteswhile
shaking at 1200 rpm. Input samples were similarly digested. Capture reactions were transferred to microspin cups (Pierce, Thermo
Fisher Scientific), centrifuged at 2,000 3 g for 30 s, and elutions used for RNA purification by RNA Clean and Concentrate-5 kits
(Zymo, > 17nt protocol).
For qPCR analysis, cDNA was generated from purified RNA using Maxima H- reverse transcriptase (Thermo Fisher Scientific)
following manufacturer’s recommendations. Amplification reactions were assembled with primer sets indicated in Table S2 and
LightCycler 480 SYBR Green I Master (Roche) following manufacturer’s protocols and read out in a Roche Lightcycler 480.
Library construction
RNA-Seq libraries were constructed from purified RNA as previously described (Van Nostrand et al., 2016). Briefly, after proteinase K
elution, the RNA was dephosphorylated (Fast AP) and cyclic phosphates removed (T4 PNK) and then cleaned using Silane beads as
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previously described (Van Nostrand et al., 2016). An RNA adaptor containing a RT primer binding site was ligated to the 30 end of the
cleaned and end-repaired RNA. The ligated RNAwas reverse transcribed (RT) into cDNA, the RNA was degraded using NaOH, and a
second adaptor was ligated to the single stranded cDNA. Library preparation was the same for input samples except that an initial
chemical fragmentation step (90C for 2 min 30 s in 1X FastAP buffer) was included prior to FastAP treatment. This chemical frag-
mentation step was designed to be similar to the fragmentation conditions used for purified Halo bound samples. The DNA was
amplified and Illumina sequencing adaptors were added by PCR using primers that are complementary to the 30 and 50 adapters.
The molarity of PCR amplified libraries were measured by Agilent Tapestation High Sensitivity DNA screentapes and all samples
were pooled at equal molarity. The pool was then purified and size selected on a 2% agarose gel and cut between 150-700 nts.
The final libraries were measured by Agilent Bioanalyzer and Qubit high sensitivity DNA to determine the loading density of the final
pooled sample. Pooled samples were paired-end sequenced on an Illumina HiSeq 2500 with read length 35 3 35nts.
Antibody Generation
To generate the sheep polyclonal anti-NSP1, anti-NSP8, anti-NSP9, and anti-NSP16 antibodies utilized in this study, NSP1, NSP8,
NSP9 and NSP16 (using QHD43415.1 as reference) were cloned into pGex (GST-tagged) and pMex (MBP-tagged), in order to pro-
duce GST- andMBP-tagged respective NSP proteins. The N-terminal GST fusions were then used as antigens to immunize sheep. A
bleed from the sheepwas taken 7 days later, after which theMBP-tagged NSP proteins were used for serum affinity purification of the
antibodies. To validate expression of the antibodies, Vero E6 cells were uninfected (mock) or infected with SARS-CoV-2 England-02
using aMOI of 0.1 or 1 (as indicated). At 72 hours post infection, the samples were harvested and the resulting whole cell lysates were
probed by western blot with either sheep anti-NSP or mouse anti-actin (Developmental Studies Hybridoma Bank JLA20, antibody
registry ID: AB_528068) primary antibodies.
Microscopy imaging
Cells were seeded on gelatin/laminin and poly-D-lysine (Sigma) coated coverslips or chamber slides (Nunc, Thermo Fisher Scientific)
and transfected with mammalian expression vectors for Halo-tagged viral proteins. After 16-24 hours, cells were incubated with
TMR-HaloTag Ligand (Promega) according to manufacturer’s instructions, washed with PBS and fixed in 4% Formaldehyde
(Pierce, Thermo Fisher Scientific). Cells were subsequently incubated in DAPI for 10 min and washed with PBS. For chamber slides,
samples were imaged directly. For coverslips, samples were washed with water and mounted with ProLong Gold + DAPI (Molecular
Probes, Thermo Fisher Scientific). We acquired images on a Nikon TS100-F widefield microscope or a Zeiss LSM800 inverted
confocal microscope, collecting in line-scanning mode with 4x line averaging using a 63x oil objective.
For staining of infected cells, cells were fixed and permeabilized in 8% formaldehyde 1% Triton, and subsequently labeled with
primary antibodies raised in sheep to SARS-CoV-2 at 1/500 dilution, followed by incubation with a rabbit anti-sheep Alexa 555 sec-
ondary antibody (Abcam, ab150182) at 1/1000 dilution and mounted with DAPI in the medium (Thermo Fisher Scientific, cat#
P36395). Cells were imaged with a Zeiss LSM 880 confocal microscope, with 1 Airy unit pinhole for all primary antibody channel ac-
quisitions and pixel size 0.07 mm x 0.07 mm. The objective lens used was a Zeiss Plan-Apochromatic 63x/1.4NA M27.
Structure modeling
NSP1 homology model
The predicted model of SARS-CoV-2 NSP1 was generated using the transform-restrained Rosetta (trRosetta) algorithm, a deep
learning-based modeling method based on the Rosetta energy minimization pipeline with additional distance and interaction re-
straints generated from co-evolution (Yang et al., 2020). All figures were generated using Pymol (https://pymol.org/2/).
NSP1-ribosome model
The model of NSP1 bound to the ribosome was generated using Modeler version 9.24(Webb and Sali, 2016). The C-terminal
sequence of NSP1 (KHSSGVTRELMRELNGG) was modeled using the structure of SERBP1 bound to the ribosome (PDB ID:
6MTE, chain w) as a template. The default Modeler parameters were used to create an alignment of NSP1 and SERBP1 and to
generate the model, and all atoms within 6A˚ of SERBP1 were included in the model to define the neighboring environment. Twenty
models were generated and the model with the lowest DOPE score was selected to visualize with Pymol (Delano, 2002).
Structural analysis of protein-RNA interactions
X-ray crystal structures and cryo-electron microscopy structures were obtained from the Protein Data Bank (http://www.rcsb.org;
Berman et al., 2000) and visualized with PyMOL (Delano, 2002). For U1 and U2 structural analysis, we used a cryo-EM structure
of the pre-catalytic human spliceosome (PDB ID: 6QX9). For 7SL structural analysis, we used an X-ray crystal structure of the human
signal recognition particle (PDB ID: 1MFQ). To examine human SRP in the context of the ribosome, we used a cryo-EM structure of
the mammalian SRP-ribosome complex (PDB ID: 3JAJ). To analyze the ribosomal ES27 expansion segment, we superimposed a
cryo-EM structure of the expansion segment (PDB ID: 6SXO) onto the complete ribosome structure (PDB ID: 3JAJ) using the PyMOL
command ‘‘super.’’ Finally, for NSP1–18S rRNA structural analysis, we usedmultiple structures of the ribosome, including structures
of the pre-40S subunit (PDB ID: 6G5H), 48S late-stage initiation complex (PDB ID: 6YAL), 80S in complex with SERBP1 (PDB ID:
6MTE), and 80S in complex with Stm1 (PDB ID: 4V88).
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Recombinant NSP1 production
NSP1 was cloned into a bacterial expression vector resulting in N-terminally tagged Halo-6xHis-tagged Nsp1. The NSP1 sequence
was PCR amplified from Addgene Nsp1 entry vector to add a N-terminal 6X HIS tag and restriction enzyme sites for digestion and
ligation into N-terminal Halo bacterial expression vector. This construct was transformed into BL21 DE3 E. coli (Agilent), expanded to
a 500mL liquid culture, and grown until OD600 reached 1.0. IPTG was added to a final concentration of 1mM. After 3 hours of IPTG
induction, bacteria was centrifuged for 15min at 50003 g. Pellet was lysed with binding buffer (50mMHEPES, pH 7.5, 20mMMgCl2,
600mMNaCl, 2mM TCEP, 10mM Imidazole, 2mM ATP, 1% Triton X-100) supplemented with ATP (2mM), protease inhibitor cocktail
(Promega), Benzonase (Sigma) and Triton X-100 (Sigma) using 5mL of lysis mix per gram of wet cell paste. Cell suspension was
rocked for 20min at room temperature and then centrifuged at 16,0003 g for 20min at 4C. Supernatant was incubated with washed
iMAC resin (Bio-Rad) and rocked for 20min at room temperature. We loaded the resin-lysate mixture into an appropriately-sized col-
umn and washed with 5 column volumes of binding buffer (50mM HEPES, pH 7.5, 20mM MgCl2, 600mM NaCl, 2mM TCEP, 10mM
Imidazole, 2mM ATP, 1% Triton X-100) followed by 10 column volumes of wash buffer (50mM HEPES, pH 7.5, 600mM NaCl, 2mM
TCEP, 20mM Imidazole, pH 8). Recombinant NSP1 (rNSP1) was eluted with 5 column volumes of elution buffer by adding 1 column
volume at a time with column flow stopped, collecting eluate after each addition, and waiting 15 min between each elution buffer
addition. We dialyzed these eluates with a 10mL Spectra-Por Float-A-Lyzer G2 (Spectrum Laboratories) into storage buffer
(50mM HEPES, pH 7.5, 150mM NaCl, 10% glycerol) at 4C using 2 exchanges, one after 2 hours and then overnight.
In vitro translation assays
Pierce 1-Step Human Coupled IVT-DNA (Thermo Fisher Scientific) in vitro translation kit was used to measure rNsp1-dependent
translation inhibition. Bovine Serum Albumin (BSA), and buffer only controls were used to control for the addition of excess protein
or changes in buffer composition. To measure translation inhibition, 5 mL in vitro translation reactions were assembled, scaled ac-
cording to manufacturer’s recommendations. The included control plasmid pCFE-GFP was used to measure translational output
of the reactions. GFP fluorescence was measured on a BioTek Cytation3 plate reader using emission filters for GFP fluorescence.
1.5 mM stock dilutions of rNsp1 and BSA were made in storage buffer (50mM HEPES, pH 7.5.,150mM NaCl,10% glycerol). Subse-
quent 10-fold dilutions were made in storage buffer to span a concentration range of 1000 nM to 1 nM for each protein in the final
reaction. 10 mL of the diluted protein solution was added to the 5 mL translation reactions, and incubated for 5 minutes at room tem-
perature prior to the addition of the GFP reporter plasmid. Duplicate reactions weremade tomeasure variability for each condition. In
addition, a buffer only control was included to measure the effect of dilution of the translation reaction by the storage buffer. After the
5 minute incubation, 50 ng of GFP reporter plasmid was added to each reaction and incubated at 30C for 4 hours prior to fluores-
cence detection. Two microliters from each reaction was measured in duplicate on a Biotek Cytation3 microplate reader using exci-
tation and emission filters for GFP. Sample readings were blanked by subtracting values obtained from the buffer only control.
Promega’s Rabbit Reticulocyte Lysate System was also used to assay translation inhibition. To measure translation inhibition,
10 mL in vitro translation reactions were assembled, scaled according to manufacturer’s recommendations. For each translation re-
action, either 10 mL of recombinant protein storage buffer or rNSP1 was added, followed by 500ng of mRNA. After 4 hours of incu-
bation at 30C, luciferase was read out using the Bright-Glo luciferase assay (Promega) or GFP fluorescence was measured, both on
a Biotek Cytation3 plate reader.
In vivo translation assays
We assayed translation in HEK293T cells transfected with mammalian expression vectors, mRNAs, or combinations of these. For
mRNA transfections of fluorescence protein translation reporters (including unmodified, +SARS-CoV2 leader
sequence, +SL1, +SL2-SL1, and +5nts), DNA templates for in vitro transcription were generated with sequences appended to the
50 end of GFP and mCherry (see Tables S4 and S5 for primers and templates, respectively) and transcribed using HiScribe T7
ARCA mRNA Kit with tailing (New England Biolabs). For Nsp1 mRNA transfection, indicated primers from Table S4 were used to
add restriction enzyme sites for cloning into pT7CFE1-CHis backbone provided in the Pierce Human 1-step Coupled IVT Kit and Hi-
Scribe T7 High Yield RNA Synthesis Kit (New England Biolabs) was used for in vitro transcription.
Using BioT transfection reagent, mammalian expression vectors for a GFP reporter and for SARS-CoV-2 viral proteins were trans-
fected into HEK293T cells seeded for imaging, as described above, or seeded in 24 well plate format. To transfect only mRNA, Lip-
ofectamine messengerMax (Invitrogen, Thermo Fisher Scientific) or TransIT-mRNA Transfection Kit (Mirus Bio) was used. For trans-
fections that included both mRNA and plasmid, Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) was used.
To measure fluorescence at 24 (leader-mCherry, no leader-GFP) or 48 hours (leader GFP, no-leader mCherry) post-transfection,
cells were trypsinized and processed for flow cytometry or transferred into black 96well plates (Nunc) for fluorescence detection on a
Biotek Cytation 3 plate reader. For flow cytometry, lifted cells were washed with CBH buffer (10mM HEPES, pH 7.4, 0.5% BSA,
Hank’s Balanced Salt Solution (GIBCO, Thermo Fisher Scientific)), resuspended with a viability dye (7-AAD or DAPI) and analyzed
on a MACSQuant Vyb. Acquistion files were analyzed with FlowJo analysis software.
SUnSET assay
To assay global protein translation, a SUnSET assay was performed as previously described (Schmidt et al., 2009). Mammalian
expression vectors were exchanged for versions that did not confer puromycin resistance and thus, for these experiments, LR re-
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actions were carried out with destination vector pB-Halo-DEST-IRES-NGFR. Resulting expression vectors drive protein expression
by a dox-inducible promoter, contain the rtTA needed for dox induction, and produce an N-terminally-tagged Halo fusion protein.
Generation of this destination vector made use of the pB-TAG-ERN backbone (a gift from Knut Woltjen; Addgene plasmid #
80476; http://addgene.org/80476; RRID:Addgene_80476)(Kim et al., 2016) and the NGFR (Truncated Human Nerve Growth Factor
Receptor) coding sequence from Addgene plasmid #27489 (a gift from Warren Pear; http://addgene.org/27489; RRID:Addge-
ne_27489)(Izon et al., 2001).
We transfected these mammalian expression vectors for NSP1 and GFP into HEK293T using BioT transfection reagent. After 3
hours, doxycycline (Sigma) was added to a final concentration of 2 mg/mL. After 24 hours, cells were incubated with puromycin
(10 mg/mL) for 10min, then washed with freshmedia, and harvested with cold PBS. Pelleted cells were lysed for 10min on ice (mixing
after 5 min) with 100uL RIPA buffer supplemented with protease inhibitor cocktail (Promega). Insoluble debris was pelleted by centri-
fuging at 12,5003 g for 2.5minutes and supernatant was run on a Bolt 4%–12%Bis-Tris Plus Gel (Thermo Fisher Scientific). Proteins
were then transferred to nitrocellulose using the iBlot transfer system (Thermo Fisher Scientific) andwestern blotting carried out using
an anti-puro antibody (clone 12D10, EMD Millipore).
SUnSET in SARS-CoV-2 infected cells
SUnSET in SARS-CoV-2 infection was performed as above with the following modifications. Cells were infected or not (mock) with
SARS-CoV-2, and 48 hpi cells were incubated with puromycin (10 mg/mL) for 20 min. Media was aspirated and cells lysed directly in
2X Laemmli’s buffer (Biorad), heated at 95C for ten minutes and run on a 4%–12%NuPAGE Gel (Thermo Fisher Scientific). Proteins
were transferred to nitrocellulose using the iBlot transfer system and probed as above.
Membrane protein reporter experiments
To assay SRP-dependent membrane protein transport to the cell surface, we monitored surface arrival of exogenously expressed
Neuronal Growth Factor Receptor (NGFR) by flow cytometry in the presence of NSPs. Mammalian expression vectors were
exchanged for versions that contained an IRES-NGFR to co-express a membrane reporter and thus, for these experiments, LR re-
actions were carried out with destination vector pB-6xHis-GFP-DEST-IRES-NGFR. Resulting expression vectors drive protein
expression by a dox-inducible promoter, contain the rtTA needed for dox induction, and produce an N-terminally-tagged His-
GFP fusion protein and a co-expressed NGFR. The GFP here is an enhanced GFP containing an amino acid substitution (A205K)
to generate a monomeric variant based on previous literature (Alberti et al., 2018).
We transfected thesemammalian expression vectors for NSP8, NSP9, NSP1DRCmutant and EED into HEK293T using BioT trans-
fection reagent, induced expression with 2 mg/ml doxycycline 24 hours after transfection, and assessed surface arrival of NGFR 24
hours after induction. To carry out flow cytometric analysis, cells were lifted with 1mMEDTA, washed once with PBS and stained with
PE-labeled anti-NGFR antibody (Biolegend; 1/600 dilution in PBS, 0.5%BSA) and analyzed on a MACSQuant Vyb. Fluorescence in-
tensity measurements were taken for GFP and PE and analyzed using FloJo analysis software.
siRNA experiments for SRP19 and SRP54
To knockdownSRP19 andSRP54, siRNAs targeting each (Dharmacon cat# L-019729-01-0005 and L-005122-01-0005, respectively)
were transfected into HEK293T cells using Lipofectamine RNAiMAX (Invitrogen) according to manufacturer’s protocols. To validate
knockdown, transfected cells were assayed by qPCR using primer sets (Table S2) to amplify each target as well as normalizer Calm3.
Transfections were carried out 48 hours prior to assaying cells, either by qPCR, membrane reporter, or membrane SUnSET (see
below) experiments.
Leader-NGFR measurements
Calu3 and Vero cells were transfected with mRNAs encoding leader-NGFR and leader-GFP using TransIT-mRNA Transfection Kit
(Mirus) and subsequently infected with SARS-CoV-2 at an MOI of 0.1. After 24 hours, cells were washed with PBS, trypsinized
and fixed in 4% PFA for 20 minutes before staining with biotinylated anti-NGFR (BioLegend) and anti-SARS-Cov-2 Spike Antibody
(Sino) and subsequently stained with PE-labeled anti-Rabbit (Thermo, P-2771MP) and PacBlue-labeled streptavidin (Thermo,
S1222). FACS was performed on a MACSquant Flow cytometer and analyzed using FloJo analysis software; FACS distributions
were compared using a 2-tailed Kolmogorov-Smirnov test. For these experiments, RNA was transcribed from a PCR template
(see Table S4) using the HiScribe T7 ARCA mRNA kit (with tailing).
Membrane SUnSET assay
To assay transport to the cell surface of all plasma membrane proteins, the SUnSET assay was adapted to puro-label surface pro-
teins as previously described (Schmidt et al., 2009), and read out by flow cytometry. Briefly, cells were incubated with puromycin as
described above, followed by two quick washes and a chase with fresh complete media for 50 min. Cells were lifted with 1mM EDTA
as described above and stained with an anti-puro antibody (clone 12D10, EMDMillipore) conjugated to Alexa-647. For these exper-
iments, NSP was expressed from the same vector described above for membrane reporter assays. Fluorescence intensity measure-
ments were taken for GFP and Alexa-647 on aMACSquant Flow cytometer and analyzed using FloJo analysis software; distributions
were compared using a 2-tailed Kolmogov-Smirnov.
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Splicing assessment experiments
IRF7-GFP splicing reporter
To assess splicing efficiency, exons 5-6 of mouse IRF7 (ENMUST00000026571.10) containing its endogenous intron were fused up-
stream of 2A self-cleaving peptide and eGFP and cloned into anMSCV vector (PIG, Addgene) (Mayr and Bartel, 2009). This construct
was co-transfected into HEK293Ts with NSP16 or GFP andmeasured 24 hours after transfection by flow cytometry (Macsquant) and
analyzed using FloJo analysis software.
5EU labeling of RNA
SARS-Cov2 or mock infected Calu3 cells and Nsp16- or GAPDH-expressing HEK293Ts were labeled with 5-Ethynyl-uridine (5EU;
Jena Bioscience) by adding 5EU containing media to cells for 20 min at a final concentration of 1mM, as previously described
(Jao and Salic, 2008). After the pulse label, cells were washed with warm PBS and lysed in RLT buffer (QIAGEN). Total RNA was iso-
lated from cells usingmanufacturer’s protocols for Qiashredder and RNeasy RNA isolation (both QIAGEN), followed by Turbo DNase
treatment (Ambion, Thermo Scientific), and Zymo RNAClean and Concentrate. For each sample, 2 mg of RNAwas used for ligation of
a unique barcoded RNA adaptor, following the relevant steps in the protocol described above in Library Construction of RNA-seq
libraries. Samples were then pooled before proceeding to biotinylation steps.
Biotinylation of 5EU labeled RNA
To biotinylate 5EU-labeled RNA, samples were first mixed, in order, with water, HEPES (100 mM), biotin picolyl azide (1 mM; Click
Chemistry Tools) and Ribolock RNase inhibitor, then added to premixed CuSO4 (2 mM) and THPTA (10mM), and finally added to
freshly prepared sodium ascorbate (12mM), as previously described (Hong et al., 2009). The click reaction was incubated for 1
hour at 25Cwith 1000rpm shaking on an Eppendorf thermomixer followed by RNA purification using > 17nt protocol for Zymo Clean
and Concentrate.
Sequential capture of biotinylated RNA
We completed three rounds of sequential capture on streptavidin beads to isolate nascent transcripts (see Figure S3B). To capture
biotinylated RNA, MyOne Streptavidin C1 Dynabeads (ThermoFisher Scientific) were first washed three times in Urea buffer (10mM
HEPES, pH 7.5, 10mM EDTA, 0.5M LiCl, 0.5% Triton X-100, 0.2% SDS, 0.1% sodium deoxycholate, 2.5mM TCEP, 4M Urea) fol-
lowed by three additional washes in M2 buffer (20mM Tris, pH 7.5, 50mM NaCl, 0.2% Triton X-100, 0.2% sodium deoxycholate,
0.2% NP-40). Washed beads were mixed with 3 parts 4M Urea buffer and 1 part biotinylated RNA and incubated for 60 min with
900rpm thermomixer shaking at room temperature.
After magnetic separation, beads were washed 3 times withM2 buffer followed by 3 washes with Urea buffer at 37C at 750rpm for
5 min. RNA was eluted from beads in 2 sequential elutions by incubating with elution buffer (5.7M guanidine thiocyanate, 1% N-laur-
oylsarcosine; both Sigma) at 65C for 2 minutes, repeating with more elution buffer for a second elution.
The elutions were pooled, diluted with Urea buffer, incubated with pre-washed streptavidin beads, washed, and eluted for 2 addi-
tional rounds exactly as described above for a total of 3 sequential captures.
Final elutions were pooled, cleaned with Zymo RNA Clean and Concentrate following manufacturer’s protocols, and carried
through RNA-seq library preparation as described above starting with the reverse transcription step.
Interferon stimulation experiments
HEK-Blue ISG cells were seeded in 96 well plates, transfected with Nsp1 mammalian expression vectors using BioT and stimulated
with 50 ng/ml human IFN-B (R&D Systems). Supernatants were assayed for alkaline phosphatase as per manufacturer instructions
using QUANTI-Blue reagent (Invivogen).
HEK293T cells were seeded in 6 well plates, transfected with either Halo-tagged GapdH, Nsp1, NSP8 and NSP9 in combination, or
NSP16 mammalian expression vectors using BioT. 24 hours later, the media was replaced with media containing 50 ng/ml human
IFN-b (R&D Systems). Expression was assayed using live cell Halo-imaging. Halo-TMR ligand was diluted 1:200 in media and added
to the culture for a 1:1000 final dilution. Samples were incubated 30 minutes at 37C, 5% CO2 and then the media was aspirated.
Wells were rinsed twice with PBS, then media was added back to the wells. Samples were incubated 30 minutes at 37C, 5%
CO2 to allow uncoupled ligand to diffuse out of the cells. Media was then aspirated and replaced, and cells were imaged by widefield
fluorescence microscopy. Cultures were ultimately harvested for RNA 24 hours later, or 48 hours post transfection.
A549s were seeded in 6 well plates, transfected with NSP1 mammalian expression vectors using Lipofectamine 2000 and stimu-
lated with 1 mg/ml HMW poly(I:C) (Invivogen) 24h after transfection. Supernatant was assayed for secreted IFN-b by ELISA (Human
IFN Beta ELISA, High Sensitivity, PBL) 24 hours after stimulation, and RNA from cells was purified and assessed for ISG gene expres-
sion as normalized to GAPDH expression (SYBR Green Master Mix, Bio-Rad). Primers used for qPCR are listed in Table S2.
50 viral leader experiments
Sars-CoV-2 Leader sequence was appended to the 50 end of GFP and mCherry reporter templates via PCR. PCR templates were
then transcribed using HiScribe T7 ARCAmRNA kit (with tailing). Leader mutants, including SL1 only, SL1/SL2 swap, and +5nts mu-
tants were likewise appended to the 50 end of fluorescent reporter templates via PCR and transcribed using Hiscribe T7 ARCA kit.
mRNA reporters were transfected in HEK293T cells with Lipofectamine MessengerMax. To measure fluorescence of mCherry and
GFP reporters, 24 hours post transfection cells were either lifted with PBS and transferred into black 96 well plates for fluorescence
readout on a Biotek Cytation 3 or trypsinized and processed for flow cytometry.
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Alignments and phylogeny reconstructions
Alignments were performed with MAFFTT (v7.407) using a local alignment (linsi–ep 0.123–reorder [in.fasta] > [out.aln.fasta]). Result-
ing alignments were visualizedwith Geneious. Pairwise distancematrices were visualizedwithMorpheus. Phylogeny reconstructions
were performed with IQTREE multicore (v1.6.12), model selection with 1000 bootstrap pseudoreplicates (iqtree -s [out.aln.fasta] -m
TEST -bb 1000 -nt 4 -o [outgroup]). Phylogenies were visualized with FigTree.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of SARS-CoV-2 viral protein binding to RNA
Sequence alignment and analysis
For Halo purifications and RNA binding mapping sequencing reads were aligned to a combined genome reference containing the
sequences of structural RNAs (ribosomal RNAs, snRNAs, snoRNAs, 45S pre-rRNA) and annotated mRNAs (RefSeq hg38) using
Bowtie2. To distinguish between the nascent pre-ribosomal RNA and mature 18S, 28S, and 5.8S rRNA, we separated each of the
components of the 45S into separate sequence units for alignment (e.g., ITS, ETS). We excluded all low quality alignments
(MAPQ < 2) from the analysis. For mRNA analysis, we removed PCR duplicates using the Picard MarkDuplicates function (https://
broadinstitute.github.io/picard/).
For each RNA, we enumerated 100 nucleotide windows across the entire RNA. For each window, we calculated the enrichment by
computing the number of reads overlapping the window in the protein elution sample divided by the total number of reads within the
protein elution sample.We normalized this ratio by the number of reads in the input sample divided by the total number of reads in the
input sample. Because all windows overlapping a gene should have the same expression level in the input sample (which represents
RNA expression), we estimated the number of reads in the input as the maximum of either (i) the number of reads over the window or
(ii) the median read count over all windows within the gene. This approach provides a conservative estimation of enrichment because
it prevents windows from being scored as enriched if the input values over a given window are artificially low, while at the same time
accounting for any non-random issues that lead to increases in read counts over a given window (e.g., fragmentation biases or align-
ment artifacts leading to non-random assignment or pileups).
We calculated a multiple testing corrected p-value using a scan statistic, as previously described (Guttman et al., 2009, 2010).
Briefly, n was defined as the number of reads in the protein elution plus the number of reads in the control sample. p was defined
as the total number of reads in the protein elution sample divided by the sum of the protein elution sample total reads and total reads
in the control sample. w was the size of the window used for the analysis (100 nucleotides). The scan statistic p-value was defined
using the Poisson estimations based on standard distributions previously described (Naus, 1982).
Because RNA within input samples are fragmented differently than the protein elution samples, we noticed that the overall posi-
tional distribution of protein elution samples was distinct from Input distributions. Accordingly, we used the remaining protein elution
samples (rather than Input) as controls for each protein. Specifically, this enabled us to test whether a given protein is enriched within
a given window relative to all other viral and control proteins. Enrichments were computed as described above. These values are
plotted in Figure 1 and Table S1.
Plotting and visualization
Enrichment plots for specific RNAs were visualized in IGV (Robinson et al., 2011) and were generated by either: (i) computing the
enrichment for each nucleotide as described above. In this case, the read count for each nucleotide was computed as the total num-
ber of reads that overlapped the nucleotide. (ii) Counting the number of RT stop sites at a given nucleotide. In this case, we compute
the alignment start position of the second in pair read and computed a count of each nucleotide.We normalized this count by the total
number of reads in the sample to account for sequencing depth generated.We then normalized this ratio by the same ratio computed
for the control sample (merge of all other protein samples) for each nucleotide.
Heatmaps were generated using Morpheus (https://software.broadinstitute.org/morpheus/). All values were included if they con-
tained a significant 100nt window with a p-value < 0.001 (see above) and minimum enrichment of 3-fold above the control sample.
Gene ontology analysis
The 66 non-N enriched mRNAs were analyzed against the Gene Ontology Biological Processes and Reactome gene sets using the
Molecular Signatures Database (MSigDB) (Liberzon et al., 2015). Significantly enriched gene sets with an FDR < 0.05 were used. To
ensure that significant gene sets were not being driven by the multiple ribosomal proteins or histone proteins, these analyses were
also carried out excluding these proteins.
Splicing analysis of 5EU data
Sequenced reads were demultiplexed according to barcoded RNA adaptor sequences ligated to each respective sample. Trimmo-
matic (https://github.com/timflutre/trimmomatic) was used to remove any contaminating Illumina primer sequences in the reads and
low quality reads. Demultiplexed and trimmed files were then aligned to a hg19 reference genome using the splice-aware STAR
aligner (https://github.com/alexdobin/STAR). Alignments were then deduplicated for PCR duplicates using PICARDMarkDuplicates
(https://broadinstitute.github.io/picard/).
Aligned read-fragments were defined as read1 and read2 contained within a paired-end read fragment along with the insert be-
tween these two reads. We defined a set of high-quality represented isoforms per gene using the APPRIS database (Rodriguez
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et al., 2013). All read-fragments that spanned any 30 splice site within an isoform of one of these geneswas retained. For each 30 splice
site spanning fragment, we classified the read-fragment as a spliced fragment if it spanned an exon-exon junction (e.g., aligned
entirely within 2 distinct exons) or an unspliced fragment if it spanned an intron-exon junction (e.g., one of the reads was contained
-or partially contained – within the intron). For each isoform, we computed an unspliced ratio by counting the total number of reads
that were classified as unspliced divided by the total number of read-fragments spanning 30 splice sites within that gene. To ensure
that the splicing ratio that we measured is a reliable metric and not inflated/deflated due to low read counts, we only included genes
that contained at least 10 read-fragments in each sample and where the total number of reads in the control and sample conditions
(when merged together) contained a significant number of reads to reliably measure a difference between the two groups as
measured by a hypergeometric test (p < 0.01).
Because different genes contain different baseline splicing ratios due to gene length and coverage, we computed a change in the
splicing ratio for each gene independently. To do this, we subtracted the unspliced ratio for each sample from the average unspliced
ratio for that gene in all of the control samples. We plotted the overall distribution of these differences in splicing ratios as violin plots
for each sample. If there is no change in splicing ratio, we would expect that some genes would have higher splicing ratios and others
lower splicing ratios but that the overall distribution would be centered around 0.
Analysis of total RNA in SARS-CoV-2 infected samples
Total RNA-Seq libraries were generated from the same mock infected and SARS-CoV-2 virally infected Calu3 samples treated with
5EU. Prior to 5EU purification, total RNA was taken and an RNA-Seq library constructed as described above using barcoded RNA
adapters. Cytoplasmic ribosomal RNAs (18S and 28S) were depleted using NEBNext ribosomal RNA depletion kit (NEB E6310L) per
manufacturers recommendations. Demultiplexed reads were aligned using Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml) to custom genomes encoding classical noncoding RNAs (ncRNAs) or human messenger RNAs (mRNAs). Expression
levels were computed for each mRNA by counting the total number of sequencing reads aligned to the mature mRNA. To normalize
across the different libraries, we computed the read counts for each sample that align to non-spliced structural non-coding RNAs –
excluding rRNA but including snRNAs, 7SL, 7SK, etc. We then divided each mRNA count by the sum of all ncRNA counts. This
normalized value for each gene per sample was then converted into a fold-change by dividing this normalized value to themean value
for both mock infected samples. The fold change of each gene relative to mock was plotted across all mRNAs as a violin plot.
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Supplemental Figures
Figure S1. Global RNA Binding Maps of SARS-CoV-2 Proteins, Related to Figure 1
(A) Protein expression gels of Halo-tagged SARS-CoV-2 proteins. Expression is visualized via AlexaFluor-660 conjugated Halo-ligand. (B) Example of eCLIP (top)
and Halo (bottom) enrichments are plotted for PTBP1 over intronic regions of ITGAD mRNA. The location of the corresponding PTBP1 recognition motif (blue
boxes) are shown. (C) Density scatterplot of the enrichment levels of PTBP1 over all human RNA regions as measured by eCLIP (x axis) compared to the
enrichment levels as measured by Halo (y axis) for all RNAs identified as significantly enriched by eCLIP. (D) Cartoon illustrating protein-adduct mediated reverse
transcriptase read stops at binding motifs (top). PTBP1 crosslink-induced truncation frequency relative to known PTBP1 motif (HYUUUYU, shown in red). (E)
Scatterplot of RNA abundance (log scale, x axis) compared to Halo enrichment (log scale, y axis) for the GAPDH protein across all 100-nucleotide windows of all
annotated human RNAs (exon and introns) are plotted. Windows with significant enrichment are shown in red. (F) Representative tracks illustrating different
mRNA binding patterns in Halo captures of NSP12 (red), NPS9 (blue), NSP15 (black), and N-protein (blue). Input tracks are presented for each mRNA (gray).
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Figure S2. NSP16 Binds to the U1 and U2 Components of the Spliceosome at Their mRNA Recognition Sites, Related to Figure 2
(A) Comparison of U1 RNA enrichment across SARS-CoV-2 Halo capture datasets. (B) NSP16 binding traces along U1 RNA between two separate captures.
Splice site recognition domain is highlighted in gray. (C) Comparison of U2 RNA enrichment across SARS-CoV-2Halo capture datasets. (D) NSP16 binding traces
along U2 RNA between two separate captures. Branch point recognition domain is highlighted in gray. (E) NSP16 immunofluorescence in Vero E6 cells infected
(or mock infected) with SARS-CoV-2 at an MOI of 0.1 for 48h. Four representative fields are displayed, with size bar indicating 10 microns. (F) Western blot
confirmation of NSP16 and NSP1 antibodies used to generate images in (E). Vero cells were infected (or mock infected) with SARS-CoV-2 at an MOI of 0.1 or 1;
(legend continued on next page)
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72 hpi cells were lysed and probed by western blot with antibodies raised against NSP1 or NSP16. (G) Imaging of HEK293T cells transfected with Halo-tagged
NSP16, NSP1, and NSP1DRC plasmids. Proteins are visualized using TMR-conjugated Halo-ligand (orange) and counter-stained with DAPI (blue). Scale bars
indicate 10 microns.
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Figure S3. NSP16 Suppresses Host mRNA Splicing, Related to Figure 3
(A) Median of raw GFP fluorescence measured in splicing reporter assay performed in HEK293T cells expressing either Halo-GAPDH (gray) or Halo-NSP16 (red).
Two independent biological replicates per condition. (B) Overview of nascent RNA-sequencing method, including 5eU nucleotide feeding, biotin click chemistry
conjugation, and biotin-streptavidin-based iterative capture methods. Human/mouse mixing experimental data illustrates selective enrichment of labeled ma-
terial over unlabeled material after three sequential captures. (C1 = capture 1 enrichment, C2 = capture 2 enrichment, etc.) (C) Violin plot depicting difference in
unspliced reads per gene (defined as the difference between number of unspliced fragment divided by total fragments spanning the 30 splice site between
(legend continued on next page)
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condition and median of all control samples) for HEK293T cells transfected with either GAPDH (gray) or NSP16 (red) for 48hrs. All four individual replicates are
presented. (D) Violin plot depicting difference in unspliced reads per gene (relative to median of GAPDH) for HEK293T cells transfected with either GAPDH, NSP9,
or NSP16 (red) for 48hrs. (E) Violin plot depicting difference in unspliced reads per gene (relative to median of the mock condition) for Calu3 cells infected with
SARS-CoV-2 virus at an MOI of 0.01 for 48 hr (red) or uninfected (gray). Biological replicates are presented. (F) Violin plot depicting fold change in total steady-
state mRNA levels (mRNA initially normalized to ncRNA and ratio is fold normalized mock treatment) for SARS-CoV-2 infected (red) compared to mock infected
(gray) samples. Data is presented for two biological replicates for each condition. (G) Normalized expression of an interferon signaling reporter upon stimulation
with IFN-b and treatment with madrasin spliceosomal inhibitor (red) or DMSO vehicle (gray). Three independent biological replicates were measured for each
condition. (H-I) Representative nascent RNA tracks from SARS-Cov-2 infected (red) and mock-treated cells (gray) along Intron 11 and Intron 12 of interferon
stimulated gene, RIG-I.
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Figure S4. NSP1 Binds to the 18S Ribosomal RNA Near the mRNA Entry Channel to Suppress Global mRNA Translation in Cells, Related to
Figure 4
(A) Comparison of 18S RNA enrichment across SARS-CoV-2 Halo capture datasets. (B) The location of NSP1 binding (orange spheres) relative to 18S binding site
(cyan) upon known structure of the 80S ribosome (gray). (C) Predicted structure of NSP1 based on Robetta modeling. The critical C-terminal amino acids required
for binding 18S (K164 and H165) are indicated as red spheres. The region of homology with SERBP1 is shown in green. The observed NSP1 binding sites on the
18S rRNA are demarcated in cyan on the structure of the human 40S ribosome (PDB: 6G5H; gray)(Ameismeier et al., 2018), relative to the mRNA path (purple;
6YAL)(Simonetti et al., 2020), and known clogging factors (E) SERBP1 (green; 6MTE)(Brown et al., 2018) and (F) Stm1 (orange; 4V88)(Ben-Shem et al., 2011). (D)
An mRNA encoding GFP was added to HeLa cell extracts along with different concentrations of purified NSP1 protein (x axis). The amount of GFP protein
measured relative to the median of replicates for a buffer only control is shown (y axis). Two independent dose titrations were performed and are shown on top of
each other. (E) Schematic illustrating puromycin tagging of newly translated proteins via the SuNSETmethod. If the level of ongoing translation is high, we expect
to detect a large amount of newly generated proteins containing puromycin; if global translation is suppressed, we expect to observe a decrease in the amount of
puromycin integrated into proteins. (F) Western blot of global puromycin incorporation into proteins of HEK293T cells transfected with either Halo-GFP (left) or
Halo-NSP1 (right). GAPDH levels were measured in the same lysates to normalize for total protein in the sample (bottom). (-) puro lanes indicate transfected
samples that were not treated with puromycin. (G) Quantification of puromycin intensity across each lane of the gel in Panel F. The ratio of puromycin signal over
total GAPDH signal is plotted for individual replicates. (H) Vero E6 cells were infected (or mock infected) with SARS-CoV-2 at an MOI of 0.01. 48hpi cells were
labeled with media containing puromycin, and lysates were probed by western blot. (I) As a control for total protein levels, after samples in (G) were run on a SDS-
PAGE gel, transferred to nitrocellulose, and total proteins were stained with PONCEAU before blocking/antibody detection of puromycin signal. (J) Normalized
GFP fluorescence intensity of GFP reporter co-transfected in HEK293T cells in the presence of the NSP1DRC mutant that does not bind to 18S (gray) or NSP1
(cyan) proteins. Three independent biological replicates were measured for each sample. Note: This experiment was performed alongside the various controls
displayed in Figure 4D and are plotted on the same scale. (K) mRNA levels of ISG54 and IFN-b following stimulation with poly(I:C) normalized to levels in un-
stimulated A549 cells. (L and M) mRNA and protein levels of IFN-b following stimulation with poly(I:C) normalized to levels in unstimulated A549 cells transfected
with NSP1DRC mutant (gray) or NSP1 (cyan). Two independent biological replicates were measured for each condition. In all panels, error bars represent
standard deviation across replicates, and dots represent individual values for each replicate. * indicates p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure S5. The 50 Viral Leader Sequence Protects mRNAs from NSP1-Mediated Translational Inhibition, Related to Figure 5
(A) A schematic of the experimental design containing two reporter RNAs encoding fluorescent proteins, without the viral leader (top) and with the viral leader
sequence appended to the 50 end of the mRNA (bottom). Viral leader represented by three stem-loops in red. (B) Representative images of HEK293T cells co-
transfected with GAPDH or NSP1 along with mCherry RNAwith or without SARS-CoV-2 leader sequence. (C) Schematic illustrating the insertion of 5 nucleotides
between the 50 cap and the viral leader sequence. NSP1 protein represented in red. (D) Quantification of mCherry expression in HEK293T cells transfected with
mCherry RNAs, fused to different 50 leader variants, and either GAPDH or NSP1. Values are normalized to the median values of mCherry levels from control
condition (GAPDHwith + mCherry). At least 3 independent biological replicates per condition. Dots represent value for each independent replicate (e.g., NSP1 -L
contains 6 independent replicates). (E) Quantification of mCherry expression from HEK293T cells transfected with Halo-tagged NSP1 WT or NSP1DRC mutant,
along with leader-mCherry expressing plasmids. Values are normalized to the median values of mCherry levels in control sample (NSP1 with + leader-mCherry).
Two independent biological replicates were measured per condition. In all panels, error bars represent standard deviation across replicates, and dots represent
individual values for each replicate. * indicates p < 0.05 and **p < 0.01.
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Figure S6. NSP8 and NSP9 Bind to the 7SL RNA Component of the SRP, Related to Figure 6
(A) Comparison of 7SL RNA second read enrichment across viral protein capture datasets (top) with region of highest enrichment for NSP8/9 boxed. Independent
expression, purification, and sequencing experiments for NSP8 andNSP9were performed and are shown. (B) Comparison of 28SRNA enrichment across SARS-
CoV-2Halo capture datasets (top). Replicate representative tracks of NSP8 (blue) and NSP9 (red) on 28S rRNA are presented below. (C) Full view of 80S ribosome
structure, interfaced with SRP (7SL RNA, yellow line), NSP9 binding sites on 7SL (red circles), and NSP8 binding sites on 7SL (dark blue circles) and on ES27
expansion segment on the 28S ribosomal RNA (light blue line). (D) Imaging of HEK293T cells transfected with Halo-NSP8 or Halo-NSP9 plasmids. Proteins are
visualized using TMR-conjugated Halo-ligand (orange) and counter-stained with DAPI (blue) nuclear stain. Size bars indicate 10 microns. (E) Vero E6 cells were
infected (or mock infected) with SARS-CoV-2 at anMOI of 0.1 for 48h, before fixing and staining with an antibody raised against NSP8 or NSP9. Cells are counter-
stained with DAPI. Size bars indicate 10 microns. (F) Western blot confirmation of NSP8 and NSP9 antibodies used to generate images in (E). Vero cells were
infected (or mock infected) with SARS-CoV-2 at an MOI of 0.1 or 1; 72 hpi cells were lysed and probed by western blot with antibodies raised against NSP8
or NSP9.
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Figure S7. NSP8 and NSP9 Inhibit M and Secretory Protein Function, Related to Figure 7
(A) Schematic illustrating Signal Recognition Particle-mediated recognition and translocation of nascent membrane and secreted proteins (left). Upon SRP
dysfunction, membrane and secreted proteins are predicted to be mislocalized and degraded (right). (B) Quantification of truncated Nerve Growth Factor Receptor
(NGFR) fluorescence normalized to eGFPfluorescence (NGFR:GFP) fromHEK293T cells transfectedwith control EEDplasmid togetherwith siRNAs targeting protein
components of Signal Recognition Particle, SRP54 and SRP19. (C) Quantification of Membrane SuNSET puromycin staining fluorescence normalized to eGFP
fluorescence (Puromycin:GFP) from HEK293T cells transfected with control EED plasmid together with with siRNAs targeting protein components of Signal
Recognition Particle, SRP54 and SRP19. Three independent replicates for control and one replicate for siRNA treatments within this experiment. (D) NGFR:GFP ratio
from Calu3 human lung epithelial cells infected with SARS-CoV-2 for 24 hr at an MOI of 0.1. Density comparison between Spike positive cells in virally infected
condition to Spike negative cells in virally infectedcondition. (E) Signal P analysis of open reading framesof SARS-CoV-2 expressedproteins utilized in study. Proteins
with greater than 0.95 predicted probability indicated Signal P algorithm are highlighted in green. (F) Top: Signal P analysis of open reading frames of various
immunoregulatory cytokines and proteins, including Interferon Beta and Beta-2-Microglobulin-Precursor. Bottom: Signal P analysis of NGFR (membrane reporter)
amino acid sequence and plot of signal peptide probability along the first 70 amino acids of NGFR sequence. In all panels, error bars represent standard deviation
across replicates, and dots represent individual values for each replicate. * indicates p < 0.05 and **p < 0.01. (G) Expression of an interferon stimulated gene reporter
upon transfection with GAPDH or NSP8 and NSP9 (in combination), followed by stimulation with IFN-b. We note that because this assaymeasures intensity across a
population of cells, any cells that are not transfected by NSP8/9 would not show this effect and would lead to a smaller overall difference than might occur within
individual cells. In contrast, NGFR and SUNSET flow cytometry measurements (B-C) represent analysis of cells expressing NSP8/9.
ll
Article
